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INTRODUCTION
6
INTRODUCTION
The clinical triad of hypertension, proteinuria and non dependent edema is a well 
recognised syndrome of the second half of pregnancy known as preeclampsia, although its 
etiology remains uncertain. Patient cases that were variants of pre-eclampsia-eclampsia 
with atypical signs and symptoms or very complicated courses of this disease process have 
been reported since the end of 19th century. Many of these descriptions of pregnancies 
complicated by an unique presentation of preeclampsia-eclampsia are representation of the 
condition now identified as HELLP Syndrome. The acronym was first suggested by L. 
Weinstein in 1982 to describe the presence of Hemolysis (H), elevated liver enzymes 
(EL) as evidence of  hepatic dysfunction and thrombocytopenia as evidence of  Low 
platelets (LP) in a women considered to have preeclampsia-eclampsia.
Numerous investigations have been undertaken since 1982 to  pursue a  better 
understanding and to enlighten the treatment of potentially life-threatening entity. Recent 
investigators  have  provided  evidence  some  cases  of  HELLP  syndrome  represent  a 
vasculopathy mediated by an abnormal concentration of vascular growth factors. However 
until the underlying etiology for preeclampsia is better defined and testing for such factors 
is commonplace, controversies in the diagnosis and management of HELLP syndrome will 
persist as its numerous clinical findings will lead to varied impressions of severity and to 
varied thresholds for intervention. Although controversy surrounds almost every aspect of 
HELLP Syndrome, the balance of current opinion is that it does exist as a distrinct entity.
HELLP syndrome has been described as first appearing from the mid second 
trimester of pregnancy until several days postpartum.
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AIM OF THE STUDY
1. To  determine  the  occurrence  and  the  course  of  HELLP  syndrome  in  all 
preeclamptic-eclamptic  cases,  and  its  clinical  presentation,  subsequent 
management and maternal and perinatal outcome.
2. To asses the extent of disease process in the mother and its effect on the fetus by 
doing necessary investigations.
3. To time the delivery so that the mother and the fetus best tolerate the delivery 
process and to give the fetus the best chance of extra uterine existence.
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REVIEW OF LITERATURE
Historical aspects of HELLP Syndrome
The preeclamptic patient with the constellation of hemolysis, hepatic dysfunction, 
and low platelets has been described in the literature for decades with early accurate 
descriptions by Prichard et al (1954) and Chesley. It was not until 1982, however, when 
Weinstein Coined the acronym HELLP Syndrome (hemolysis, elevated liver enzymes 
and low platelets) that clinicians could more easily recognise and discuss this group of 
patients with remarkable hepatic involvement by severe preeclampsia. Since Weinstein's 
publication, numerous reports of this syndrome have been published.
Reviewing  literature  reveals  the  confusion  and  considerable  controversy 
concerning  the  existence,  definition,  incidence,  diagnosis  and  management  of  this 
syndrome. Goodlin considered it an early form of severe preeclampsia and labelled as a 
great imitator, impending gestosis, EPH (edema, proteinuria, hypertension), Gestosis type 
B  and  extended  toxemia  syndrome.  Weinstein  considered  it  an  unique  variant  of 
preeclampsia,  while  Mackenna  and  Colleagues  considered  it  as  misdiagnosed 
preeclampsia.
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PATHOPHYSIOLOGY           
HELLP SYNDROME:
Possible Pathophysiology
Inciting Agent(s): Sudden Large Volume Fetal/Decidual Cell Traffic? Vasospasm? 
Vascular Repair Deficiency? , Unknown(s)?

Vascular-Endothelial Dysfunction

Platelet Aggregation – Consumption

Fibrin Activation – Consumption

Selective Organ(s) Ischemia-Insufficiency

                                               Diverse Symptomatology 
It has been accepted that theory of disequilibrium in prostanoid metabolism in its 
etiology.
RED BLOOD CELL MORPHOLOGY
Fragmented red blood cells are present in women with HELLP Syndrome, but the 
amount  of  fragmentation  often  does  not  correlate  with  the  degree  of  multi  organ 
involvement that is reflected by other laboratory tests.
PLATELETS
The normal life span of a platelet is 8-10 days. In pregnancies complicated by 
preeclampsia, the life span of a platelet is reduced to 3-5 days. A further reduction in 
platelet life span and structural integrity is observed in women with HELLP syndrome, 
leading to further platelet aggregation and destruction. The altered platelet membrane in 
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HELLP syndrome releases arachidonic acid and other vasoactive amines, causing further 
vasoconstriction and  vasospasm and  accelerating platelet aggregation and  destruction. 
Platelet activating factor (PAF), a potent activator of platelet aggregation, appears not to 
be altered by preeclampsia. One of  the serum inhibitors of  PAF is reduced.  Platelet 
activation and alterations in plasminogen activation are involved in the pathogenesis of this 
disorder. Beta-thrombomodulin is a platelet specific protein whose levels become elevated. 
Early in the HELLP syndrome,  there is probably a procoagulatory imbalance in the 
placental microcirculation.
RENAL COMPROMISE 
A  small  percentage  of  HELLP  syndrome  patients  develop  significant  renal 
compromise. The disease spectrum ranges from transient elevations of serum creatinine 
concentrations to acute renal failure with temporary and reversible acute tubular necrosis 
(ATN) to permanent and irreversible renal failure with cortical necrosis.
Most commonly HELLP Syndrome involves smaller terminal arterioles yielding a 
process with characteristic histological features. The classic hepatic lesion associated with 
HELLP syndrome is periportal or focal parenchymal necrosis in which hyaline deposits of 
fibrin like material can be seen in the Sinusoids. Less frequently larger vessel disease can 
impact wider vascular distributions in the liver with more catastrophic outcomes such as 
hepatic infarction and subcapsular hematoma. This large vessel disease is more readily 
visible by imaging studies such as MRI and CT scanning. The most common site of 
hepatic rupture is the anterior superior aspect of the right lobe of the liver, and liver 
ruptures have been reported as early as 16 weeks gestation to 3 days post-partum. 
Pathogenesis of HELLP syndrome is associated with factor V R 500 Q mutation 
(Brenner et al. 1996) Activated Protein C resistance resulting from mutation in coagulation 
factor V has recently emerged as the leading cause of thrombosis.
Patients with pure preeclampsia and HELLP Syndrome will have significantly 
higher level of serum C-erb B-2 encoded oncoprotein fragment P105 (Meden et al. 1997)
Lower  beta  B-subunit  Inhibin production  in  extra  villous trophoblast  cells in 
HELLP syndrome demonstrates that this subunit might have an important role in the 
pathogenesis of HELLP syndrome.
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INCIDENCE
Based on 454 pregnancies with HELLP syndrome managed at the University of 
Mississippi Medical Center between 1980 and 1991 and 442 pregnancies cared for at the 
University of Tennessee-Memphis between 1977 and 1992, approximately one third of 
patients will have their first manifestation of HELLP syndrome diagnosed postpartum, of 
the two thirds of women who are first diagnosed with HELLP syndrome antepartum, 
10% will be identified before 27 weeks, 20% in pregnancies beyond 37 weeks, and the 
majority 70% occurring between 27 and 37 weeks gestation. The earliest recorded case of 
HELLP Syndrome in Mississippi was at 20 weeks, although a diagnosis before 25 weeks 
is infrequent.
The incidence is highest among older, white and multiparous patients. Moreover 
the incidence is higher in preeclamptic patients with delayed diagnosis and/or delayed 
delivery.
CLINICAL PRESENTATION
Patients with HELLP syndrome may present with various signs and symptoms, 
none  of  which  are  diagnostic  and  all  of  which  be  found  in  patients  with  severe 
preeclampsia-eclampsia without HELLP syndrome.
Prodromal Symptoms include (Portis et al., 1997)
1. Weakness and fatigue (90%)
2. Right upper quadrant and/or epigastric pain (90%)
3. Nausea and Vomiting (50%)
4. Headache
5. Change in vision
6. Increased tendency to bleed from minor trauma
7. Jaundice
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8. Diarrhoea
9. Shoulder or neck pain
Signs
1. Significant weight gain with generalised edema (55%)
2. Proteinuria > 2+ (85%)
3. Diastolic Blood Pressure > 100 mm Hg (69%)
Sibai et al (1990) noted that the commonest symptom was epigastric and/or right 
upper quadrant pain. In Weinstein reports (1982/1985) nausea or vomiting and epigastric 
pain were the most common symptoms. Although the contribution of right upper quadrant 
or epigastric pain to the risk status of a pregnant patient is difficult to quantify, it can be 
used to assess whether the patient is at high risk for development of HELLP syndrome.
A diurnal pattern exists in the clinical symptoms of HELLP syndrome that is 
characterised by an exacerbation during the night and recovery during the day. There is 
considerable delay between the  onset  of  symptoms and  the  fulfillment of  diagnostic 
laboratory criteria (Koenen SV et al 2006).
It is important to appreciate that severe hypertension (systolic blood pressure  > 
160 mm Hg, diastolic blood pressure > 110mm Hg) is not a constant or even a frequent 
finding in HELLP syndrome (Sibai et al 1986). Esan et al (1997) reported that HELLP 
syndrome can occur  after  a  normal delivery in a  woman whose blood pressure has 
remained normal throughout the antenatal period.
Jaundice  is  a  rare  complication  and  hyperbilirubinemia  may  result  from  a 
combination of hemolysis and liver cell necrosis. However it is unusual for icterus to be 
clinically apparent. 
Conversely,  hemoglobinuria is a more common finding when complicated by 
disseminated intravascular coagulation.
Donaldson  (1978)  reported  that  some  may  experience  visual  disturbances. 
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Neurological affection  can  also  result.  The  risk of  opportunistic  infections  may be 
increased in patients with HELLP syndrome, because of generalised (Both B&T Cell) 
immunosuppression  and  profound  decrease  in  monocyte  phagocytic  and  bactericidal 
activity (Cunningham et al. 1993).
Maternal ascitis is frequently found at Caesarean delivery in 65% of patients with 
HELLP syndrome (Woods et al 1992).
LABORATORY DIAGNOSIS
The  diagnosis  of  HELLP  Syndrome  is  based  on  laboratory  evidence  of 
microangiopathic  hemolytic  anemia,  hepatic  dysfunction  and  thrombocytopenia  in  a 
patient suspected to have preeclampsia. In a patient with HELLP syndrome, a peripheral 
blood smear often will have evidence of schistocytes, burr cells and helmet cells which 
reflect  damaged  erythrocytes.  Increases  in  Lactic  dehydrogenase  (LDH)  levels  and 
decreases in serum Haptaglobin levels are sensitive early markers of HELLP syndrome. 
Thrombocytopenia is the principal and earliest coagulation abnormality that is present in 
all women with HELLP syndrome.
Liver dysfunction is reflected by variably elevated serum concentration of aspartate 
amino transaminase (AST), alanine aminotransaminase (ALT) and LDH. Indirect levels of 
bilirubin usually are minimally elevated except in patients with advanced severe disease. 
Raised  total  Lactate  dehydrogenase  isoenzyme  is  usually reflected  in  elevations  of 
isoenzymes 5 (LDH 5 liver).
HELLP syndrome patients will have high plasma fibronectin and D-dimer values, 
lower Antithrombin III and protein C activity (Paternoster et al. 1995).
HELLP  syndrome  should  be  taken into  account  in  the  case of  unexplained 
elevated levels of MSHCG and MSAFP in the second trimester especially in the rare 
event of combined elevation of both markers (Morssink-LP 1997).
Iioka (1996) reported that increased level of Human Hepatocyte growth factor 
may be useful in the early detection of HELLP syndrome.
Significant over expression of Serum Amyloid A (SAA) in HELLP syndrome 
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patients that could function as markers for the HELLP syndrome (Heitner JC et al 2006).
A single A > G nucleotide substitution at position - 670 in the maternal but not 
neonatal TNFRSF6 gene coding for Fas is associated with a higher risk for HELLP 
syndrome (Sziller et al 2006). Significantly there will be a decreased expression of Pro 
apoptotic proteins BNip3 and Nix in the placenta of HELLP syndrome patients (Stepan 
H. et al 2005).  O Rh-negative had HELLP syndrome associated with an increase in risk 
by a factor of 3.1 (Sezik M & Coworkers 2002).
CLASSIFICATION
A three-class system was formulated because the maternal platelet count and the 
serum LDH concentration appear to best reflect the severity of the disease process as it 
worsens and the rapidity of recovery from HELLP syndrome. Women with Class I 
HELLP  syndrome  have  a  maternal platelet  nadir  of  < 50,000  /µL in addition  to 
laboratory evidence of microangiopathic hemolytic anemia and altered liver enzymes. 
Patients  with  class  II  HELLP  syndrome  have  a  platelet  nadir  of  >50,000  but  < 
1,00,000/µL, and those with class III disease have a platelet count of > 1,00,000 but < 
1,50,000/µL 
17
HELLP SYNDROME
Classification Systems
Mississippi 3-class (Martin et al) Tennessee (Memphis)
THROMBOCYTOPENIA COMPLETE
CLASS 1 : < 50,000 /  µL Platelets < 1,00,000/µ L Platelets
CLASS 2 : > 50,000 - < 1,00,000/ µ L LDH > 600 IU/L
CLASS 3 : > 1,00,000 - < 1,50,000/ µ L AST > 70 IU/L
HAEMOLYSIS + HEPATIC 
DYSFUNCTION
INCOMPLETE
LDH > 600 IU/L Only one or two of above present
AST and/or ALT > 40 IU/L
All must be present to qualify...
Other classifications of HELLP Syndrome
Platelet Count AST LDH
Sibai et al 11 < 1,00,000/mm3 > 70 IU/L > 600 IU/L
Van Pampus13 < 1,00,000/mm3 > 50 IU/L >600 IU/L
Visser and 
Wallenburg14 < 1,00,000mm
3 > 30 IU/L *
DIFFERENTIAL DIAGNOSIS OF PRE ECLAMPSIA - HELLP SYNDROME
• THROMBOTIC MICROANGIOPATHIES
Thrombotic Thrombocytopenic purpura - Hemolytic Uremic Syndrome 
Sepsis-Induced or Drug Induced Microangiopathic Hemolytic Anemia.
• FIBRINOGEN CONSUMPTIVE DISORDERS - DIC
AFLP-Acute Fatty Liver of Pregnancy
Severe Hypovolemia/Hemorrhage (Abruption/Amniotic Fluid Embolism)
Sepsis Induced.
• CONNECTIVE TISSUE DISORDERS
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SLE - Systemic Lupus Erythematosis
• PRIMARY RENAL DISEASE
• MISCELLANEOUS
Viral Hepatitis Kidney Stones
Hyperemesis gravidarum Gastroenteritis
Gallbladder disease Diabetes Insipidus
Peptic Ulcer Hepatic encephalopathy
Appendicitis Cholestasis of Pregnancy
MANAGEMENT
Reported modalities used to treat or reverse HELLP Syndrome (Sibai et al 1990)
I PLASMA VOLUME EXPANSION
• Bed rest
• Crystalloids
• Albumin 5% to 25%
II ANTITHROMBOTIC AGENTS
• Low dose aspirin
• Dipyridamole
• Heparin
• Antithrombin III
• Prostacyclin infusions
• Thromboxane Synthetase inhibitor (Dazoxiban)
III IMMUNOSUPPRESSIVE AGENTS
• Steroids
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IV MISCELLANEOUS
• Fresh frozen Plasma infusions
• Exchange Plasmapharesis
• Dialysis
Intravenous  immunoglobulins  might  be  an  attractive  alternative  treatment  in 
persistently severe HELLP Syndrome (O-Pourrat et al 1992).
Another  intervention to  interrupt  or  ameliorate the  clinical course of  HELLP 
Syndrome includes the administration of nitric oxide.
Steroids and the HELLP Syndrome 
"DEXAMETHASONE RESCUE" for HELLP SYNDROME
ANTEPARTUM:  10 mg IV q 12 h
1. Whenever < 100,000/ µL Platelets
2. If Platelets 100,000 - 150,000/µL AND
Eclampsia Severe Hypertension
Epigastric pain "Fulminant Disease"
POSTPARTUM:  10 mg IV q 12 h x 2, then 5 mg IV q 12h x 2 individualised
1. Whenever antepartum steroids given to avoid rebound
2. Stop regimen after recovery evident (platelets > 100,000/ µL and LDH is trending 
downward and patients underlying preeclampsia / eclampsia is ameliorating
The  mechanism of  action is unknown but  appears to  alter  the  final steps in 
endothelial cell disruption Isler et al demonstrated intravenous dosing was superior to 
intramuscular dosing for several outcome variables including improving urine output and 
greater improvement in Laboratory values.
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High-Dose Glucocorticoid Therapy for severe HELLP Syndrome
For most patients with HELLP syndrome, 10 mg intravenous dexamethasone every 6 
hours for 2 doses followed by 6 mg intravenous dexamethosone every 6 hours for 2 
additional doses.
For select patients at high risk, including those with profound thrombocytopenia (<20,000/
mm3) or with central nervous system dysfunction (i.e. blindness, paralysis), 20 mg 
intravenous dexamethasone every 6 hours for upto 4 doses.
The duration of action of this medication is limited and patients may experience a 
worsening of their laboratory studies 48 to 72 hours after dosing with glucocorticoids. We 
term this as Rebound phenomenon. Steroid treatment, therefore, is not curative but may 
create a "Window of opportunity" for intervention before the maternal condition may 
again  deteriorate.  Because  glucocorticoids  do  not  appear  to  alter  the  underlying 
pathophysiology, delivery remains the only definitive therapy.
MATERNAL MORBIDITY AND MORTALITY
Maternal morbidity has been reported to be as high as 24% in one series of 
patients, but should be infrequent in an optimal medical and obstetric environment. The 
maternal death  does  not  occur  by a  common  pathway,  but  instead by a  variety of 
mechanisms.  In  a  review of  34  HELLP  syndrome  related  mortalities,  the  authors 
discovered that the presenting symptom in 90% of patients who died was nausea-vomiting 
and right upper quadrant pain, the mean gestational age was 31 weeks, death occurred by 
a  variety of  pathologic processes,  including sepsis,  shock hemorrhage,  intra  cerebral 
bleeding and cardiopulmonary failure. Approximately one in six (16%) maternal deaths 
was attributed to hepatic complications. A large percentage of maternal deaths attributed to 
central nervous system catastrophic events. The most important biochemical marker for 
maternal mortality is bilirubin levels. Maternal mortality was statistically higher in cases 
with jaundice (Demir SC et al 2006).
The diverse etiology of maternal mortality in HELLP syndrome is
Cardiopulmonary Failure
Coagulopathy
21
Intracerebral Hemorrhage/stroke
Hepatic Rupture
Post-Cesarean Shock
Multi organ Failure
Miscellaneous Co-morbidities
Serious maternal morbidity is observed in patients with HELLP syndrome.
From Sibai et al (2003)
1. Disseminated intravascular coagulopathy 21%
2. Abruptio placentae 16%
3. Acute renal failure 8%
4. Severe ascitis 8%
5. Pulmonary edema 6%
6. Pleural effusions 6%
7. Cerebral edema 1%
8. Retinal detachment 1%
9. Laryngeal edema 1%
10. Subcapsular liver hematoma 1%
11. Acute respiratory distress syndrome 1%
Patients with Class 1 disease are at the highest risk for associated morbidity, with 
proportionately less observed in women with Class 2 HELLP Syndrome.
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Associated DIC is an important aggravating factor, often leading to deterioration 
of the maternal status, Van Dam et al (1989) suggested a semi quantitative DIC scoring 
system introduced by Hellgren et al (1984). This DIC score is based on platelet count less 
than 100 x 10 9/7,  Prothrombin time < 70%, antithrombin III activity < 80%, fibrin 
degradation  products  over  40  mg/L  and  fibrinogen  <  300  mg/dl.   Three  or  more 
pathologic tests were considered as manifest DIC and two as suspected DIC. DIC score 
may  be  a  sensitive index  for  detecting  deteriorating maternal  condition  in  HELLP 
syndrome and its use could reduce maternal morbidity and mortality from DIC.
A rare but interesting complication of HELLP Syndrome is transient Diabetes 
Insipidus (Mabie & Sibai 16  1990).   It  is characterised by a  resistance to  arginine 
vasopressin mediated by excessive vasopressinase. It is postulated that elevated circulating 
vasopressinase may result from impaired hepatic metabolism of the enzyme.
The best prophylaxis against development of life threatening complications is early 
diagnosis and  termination  of  pregnancy after  stabilisation of  the  maternal condition, 
consisting of magnesium sulphate infusion, antihypertensive treatment with dihydralazine 
or  calcium antagonists,  steroids etc.  As prophylaxis against postpartal  worsening of 
HELLP  syndrome,  curettage  of  the  uterus  and  continuation  of  the  treatment  with 
antihypertensives and dexamethasone have been recommended.
PERINATAL MORBIDITY AND MORTALITY 
Perinatal morbidity and mortality are increased in women with HELLP syndrome 
primarily because of prematurity. No specific neonatal pathology due to maternal HELLP 
syndrome was found.
Perinatal mortality 33% (Sibai et al 1986, Eeltink et al 1993) reported
• Small for gestational age 44%
• Perinatal asphyxia 21.6%
• Neonatal respiratory distress 43.2%
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• Hyperbilirubinemia 44.7%
• Persistent ductus arteriosus 16.2%
• Thrombocytopenia 34%
• Hypoglycemia 16.2%
CAUSES FOR PERINATAL DEATH
1. Abruptio placentae
2. Intrauterine asphyxia
3. Prematurity
The combination of HELLP syndrome and eclampsia results in a greater number 
of preterm infants with lower birth weights and higher mortalities than eclampsia alone.
IMMUNOLOGY OF HELLP SYNDROME
Pre eclampsia has been considered for a number of years by many investigators to 
result at least in part, from disordered immunologic processes. The studies that support 
this belief, list the increased incidence in primigravida, the increased risk in pregnancies 
with an increased volume of trophoblastic tissue, pregnancy with a new partner, previous 
use of barrier contraceptive and pregnancy after oocyte donation. Since HELLP syndrome 
appears to be atypical form of preeclampsia, it too could result from disordered immunity.
Increased plasma levels of anaphylotoxins C3a and C5a have been demonstrated 
in patients with preeclampsia / HELLP syndrome. Depressions of both T-cell and B-cell 
potential and impaired monocyte handling of intracellular pathogens have been reported in 
pregnancies complicated by HELLP syndrome. This immune dysfunction preceded the 
laboratory diagnosis of preeclampsia by 7-14 days.
Haeger et al (1996) suggested that inflammatory mechanisms may participate in 
the pathophysiology of severe preeclampsia since increased release of Tumor necrosis 
factor alpha (TNFα) and interleukin 6 in women with HELLP Syndrome.
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Dudley  et  al  (1996)  supported  the  hypothesis  that  the  regulation  of  IL-12 
production  and  metabolism is  abnormal  in  women  with  preeclampsia  and  HELLP 
Syndrome, perhaps contributing to the immunologic alterations characteristics of these 
disorders.
Antiphospholipid antibodies may play a role in the pathogenesis of HELLP 
syndrome (Nagayama et al 1997).
PATIENT TREATMENT:  The 12-Step Approach
Successful management of pregnancy complicated by HELLP Syndrome requires 
early recognition and the institution of the appropriate therapy.
1. ANTICIPATE AND MAKE THE DIAGNOSIS
Once the diagnosis of  HELLP Syndrome is suspected,  appropriate laboratory 
testing is indicated.  In  its  early phases,  HELLP  syndrome  can  exhibit only modest 
increases in LDH,  AST and ALT levels and mild thrombocytopenia (Class 3).   The 
patient with evidence of preeclampsia and right upper quadrant pain and nausea must be 
seriously evaluated to rule out HELLP syndrome. Timely diagnosis facilitates the best 
possible outcome for a mother and her unborn child.
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HELLP SYNDROME: Risk Factors for
Significant Maternal Morbidity
• LABORATORY • CLINICAL
Platelets < 50,000/ µ L Epigastric pain
LDH > 1400 IU/L Nausea
AST > 150 IU/L Vomiting
ALT > 100 IU/L Eclampsia
Uric Acid > 7.8 mg/dl Severe Hypertension
CPK > 200 IU/L Placental Abruption
Creatinine > 1.0
2. ASSESS THE MATERNAL CONDITION
The basic laboratory screening for the patient with suspected HELLP syndrome is 
a complete blood count with platelet levels, urinalysis, serum creatinine, LDH, uric acid, 
indirect and total bilirubin levels, and AST/ALT.   Tests for prothrombin time, partial 
thromboplastin time, fibrinogen and fibrin split products are reserved for those women 
with a platelet count much below 1,00,000/ µL. They are particularly useful in women 
with platelet counts of 50,000 or less.
Serial assessments of the platelet count,  LDH, and liver enzymes are reported 
usually every 12-24 hrs or more frequently if clinically indicated.
3. ASSESS THE  FETAL CONDITION:    DELIVER SOONER  OR 
LATER?
HELLP syndrome is an atypical variant of severe preeclampsia and, as such, the 
only definitive treatment  is delivery and  removal of  chorionic villi and  the cytotoxic 
factor(s)  that  it  produces.  The  timing of  delivery depends  on  a  number  of  factors, 
including the severity of the maternal condition, fetal condition and placental reserve, and 
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the gestational age. The facilities available to care for this high risk mother and often 
preterm infant  also  will influence  the  location  of  the  delivery,  with  transport  often 
necessary before delivery to a hospital equipped to manage these at risk mothers and 
babies.
A National Institute of Health consensus panel in 1994 recommended that all 
patients with pregnancies between 24 and 34 weeks gestation at risk for preterm delivery 
be  considered  candidates  for  corticosteroid  therapy  to  enhance  fetal  lung 
maturation/neonatal pulmonary function even if delivery might not be postponed the ideal 
24-48 hour period.  ACOG committee on Obstetrical practice has now adopted these 
recommendations.
The longest interval we have used corticosteroids to postpone delivery in very 
preterm (24 weeks) patients with HELLP syndrome is 19 days.
4. CONTROL BLOOD PRESSURE
5. PREVENT SEIZURES WITH MAGNESIUM SULPHATE
It  is  recommended  that  all  HELLP  syndrome  patients  receive  intravenously 
infused MgSO4 given as a 4-6 gm intravenous bolus followed by a constant infusion rate 
of 1.5 - 4 gm/hr individualized to the patient. Continuation of the infusion 48 hrs or more 
into the  puerperium occasionally is needed until evidence of  recovery from HELLP 
syndrome is apparent.
6. MANAGE FLUID AND ELECTROLYTES
7. EXERCISE JUDICIOUS HEMOTHERAPY
8. MANAGE LABOUR AND DELIVERY
Current hospital treatment of the patient with HELLP syndrome in United States 
includes careful assessment of the maternal and fetal status, with delivery effected soon 
thereafter.
The presence of this syndrome is not an indication for immediate delivery by 
caesarean section; such an approach might prove detrimental for both mother and fetus. 
27
Cervical  status  and  inducibility  are  important  considerations  when  determining  the 
likelihood of successful vaginal delivery in patient with HELLP syndrome.
Management protocol for the HELLP Syndrome patient requiring caesarean section 
delivery
1. General anesthesia
2. Ten units of platelets prior to surgery if platelet counts < 50,000/cu mm.
3. Vertical skin incision rather than a Pfannenstiel incision to minimise blood loss.
Briggs et  al  concluded  that  for  women  with  antepartum  HELLP  syndrome 
delivered by caesarean  section,  the  frequency of  wound  complications is not 
influenced by type of skin incision or time of skin closure (Primary or delayed).
4. Spontaneous placental rather than manual extraction at caesarean is associated 
with a decreased blood loss, and less postpartum endometritis.
5. In situ rather than exteriorization for uterine repair is associated with less uterine 
and adnexal trauma.
6. Bladder flap (vesicouterine peritoneum) should be left open.
7. Subfascial drain (24 to 48 hours).
8. Subcutaneous drain may be considered if the skin is approximated.
9. Subcutaneous  tissues  should  be  approximated  with  sutures  as  evidenced  by 
randomized trials and meta analysis for skin closure at caesarean delivery.
10. Post operative transfusions as needed.
11. Intensive monitoring for 48 hrs postpartum.
ANAESTHESIA
• Maternal analgesia can be provided by intermittent infusion of butorphanol or 
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meperidine with promethazine.
• Local infiltration 1% xylocaine for carefully controlled and skillfully executed non 
operative vaginal delivery.
• Epidural anesthesia and pudendal block is contraindicated.
• General anesthesia is the method of choice for caesarean delivery.
• When coagulopathy is evident before surgery, intradural anaesthesia (low doses of 
Bupivacaine and fentanyl) is a safe option provided hemodynamic stability is 
assured (Blasi et al 1997).
9. OPTIMIZE PERINATAL CARE
10. INTENSIVELY TREAT THE POSTPARTUM PATIENT
• The  diagnostic  criteria  for  HELLP  syndrome  may  develop  antepartum  or 
postpartum. Sebai and associates revealed that 70% had evidence of the syndrome 
antepartum and 30% developed the criteria postpartum.
• In the postpartum group, the time of onset of the manifestations ranged from a 
few hours to 7 days, with the majority developing within 48 hours after delivery.
• HELLP  syndrome  may  be  diagnosed  postpartum  following 1  of  3  clinical 
scenarios:
1. Worsening of antepartum severe preeclampsia with delivery not yet altering the 
time course of the disease.
2. New onset of severe preeclampsia postpartum.
3. Rebound  deterioration  of  a  patient  with  antepartum HELLP  syndrome  after 
exposure to corticosteroid antepartum.
• Patients in this group are at increased risk for the development of pulmonary 
edema and acute renal failure.
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• The goals of therapy postpartum differ compared with antepartum and are aimed 
solely at improving the maternal status.
• Management  of  seizure prophylaxis is similar to  the  antepartum patient with 
HELLP syndrome, including the need for MgSO4.
• Hypertension control may be more aggressive, because there is no longer concern 
about compromising the uteroplacental circulation in the postpartum patient.
• Martin and coworkers recommended the trial of  plasma exchange with fresh 
frozen plasma be considered in HELLP syndrome that persists past 72 hours from 
delivery and in which there is evidence of a life threatening microangiopathy.
11. REMAIN  ALERT  TO  THE  DEVELOPMENT  OF  MULTIPLE 
ORGAN SYSTEM FAILURE
12. COUNSEL ABOUT FUTURE PREGNANCIES
During the postpartum recovery period after a pregnancy with HELLP syndrome 
or at a later time remote from the index pregnancy, patients often ask for guidance about 
the recurrence risk for hypertension in general and HELLP syndrome specially in future 
pregnancies.
Currently there is no preventive therapy for recurrent HELLP syndrome. Birth 
weight and gestational age are the most important factors in predicting the course of a 
subsequent pregnancy.  
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SUBSEQUENT PREGNANCY COMPLICATIONS:  SIBAI ET AL (1995)
1. Pre-eclampsia 19%
2. Preterm delivery 21%
3. IUGR 12%
4. Abruptio placentae  2%
5. Perinatal death  4%
6. HELLP Syndrome 3-5%
7. Chronic Hypertension  4%
Recurrence Risk for HELLP Syndrome or Preeclampsia
HELLP Syndrome Pre eclampsia
Sullivan et al 19 – 27% 23 - 43%
Lie 1998 - 13%
Van Pampus et al 2% 16%
Chames et al 6% 55%
Beinder  et  al  1996  reported  that  recurrence  of  HELLP  Syndrome  in  four 
consecutive pregnancies in a patient.
Infants born to pre eclamptic mothers who develop HELLP Syndrome have an 
increased need for resuscitation at delivery and a higher incidence of postnatal cardio 
pulmonary instability (Raval et al 1997).
Sibai et al (1995) reported that there is no evidence that oral contraceptives should 
be contraindicated after HELLP syndrome.
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MATERIALS AND METHODS
Analysis of 200 cases of preeclampsia - eclampsia during the year 2005-2006 in 
Government R.S.R.M.  Hospital, Chennai to  determine the occurrence and course of 
HELLP Syndrome in order to make a timely intervention and to render optimal patient 
treatment, a better maternal and perinatal outcome.
The patients were divided into 3 groups
1. Group of Mild Preeclampsia
2. Group of Severe Preeclampsia
3. Group of Eclampsia
History regarding age,  parity,  gestational age,  menstrual history and  pervious 
illness were noted.  A thorough general and other systemic examination were done with 
obstetric examination.
The observations done were
1. Weight of the patient
2. Albuminuria
3. Blood Pressure
4. Haemoglobin
5. Platelet count
6. Peripheral smear
7. Serum Bilirubin estimation
8. SGOT estimation
9. SGPT estimation
10. BT
11. CT
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12. Serum fibrinogen
13. Sr. LDH estimation
14. Blood urea and serum uric acid estimation
15. Serum Creatinine estimation
16. Fundus examination
Group I
It consists of 68 cases of mild pre-eclampsia. It includes 40 cases of primi and 28 
cases of multi, whose systolic blood pressure was between 130-150 mm. Hg and diastolic 
between 90-100 mm. Hg with proteinuria and pedal  edema.
These  patients  were  advised  bed  rest  in  left  lateral  position  and  given only 
sedation.
Group II
It consists of 100 cases of severe preeclampsia, includes 52 cases of primi and 48 
cases of  Multi. This group of patients had history of headache,  giddiness and visual 
disturbances.
Urine showed proteinuria and there was Oedema over both legs in all cases. These 
patients were kept under strict bed rest, daily weight, daily urine for proteinuria and BP 
estimation were done. Since, these patients had systolic blood pressure between 150-200 
mm. Hg and diastolic blood pressure between 110-130 mm.Hg, patients were given Tab. 
Alphamethyldopa, Tab. Nifedipine and Inj. Pethidine 100mg depending upon the blood 
pressure.
Daily urine output was measured and the patients were advised to lie on the left 
lateral position. The uterus was examined for tenderness and tenseness and growth.
Group III
It consists of 32 cases of Eclampsia, includes 24 cases of Antepartum Eclampsia, 
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(Primi 13 cases and 11 cases of Multi), 3 cases of intrapartum Eclampsia (1 primi and 2 
multi) and 5 cases of postpartum eclampsia (3 cases of primi and 2 cases of multi).
All  patients  were  kept  in  Eclampsia  ward.  The  management  was  done  by 
monitoring blood pressure every 2 hours, continuous bladder drainage, intake output chart 
was maintained along with intravenous fluids, antibiotics and MgSO4 regime.
Intermittent suction was done and oxygen (O2) kept ready for emergency.
METHOD OF COUNTING PLATELETS
Rapid work is necessary in order to prevent clumping of the thrombocytes. Rees 
& Eker diluting fluid drawn upto 1 mark in the red pipette. Blood from a freely bleeding 
puncture is drawn exactly to the 0.5 mark and finally the diluting fluid is quickly drawn to 
the 101 mark. This gives a blood dilution of 1:200. The blood and diluting fluids are 
immediately mixed by shaking for about 2 mts. The counting chamber is filled at once and 
10 mts are allowed for the corpuscles to settle before counting is begun. The count is 
made with high power dry objective and with the 10x ocular in the manner described for 
counting erythrocytes. A central count of the thrombocytes should always be made at the 
same time with the same diluting fluid and exactly the same technique. Platelet count were 
also obtained from peripheral smear.
Platelets are disc shaped being 2-4 μm in diameter and 0.5 to 1mm in thickness. 
They have no nucleus and their cytoplasm has many azurophil granules which in blood 
films  tend  to  be  concentrated  in  the  middle.  The  precursor  for  the  platelet  is 
megakaryocytes. The platelets are formed by fragmentation and detachment of delicate 
processes from cytoplasm of  megakaryocyte.  The  normal platelet  count  varies from 
140000 to 440000/mm3. A count below 100000/mm3 can be taken as thrombocytopenia.
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PERIPHERAL SMEAR
Spreading the Film
Properly spread film is essential to accurate work.
1. The slides and cover glasses must be perfectly clean
2. Drop of blood must not be too large
3. The work must be done quickly
The blood is obtained from the finger tip. Take a small drop of blood on a clear 
slide about 3/4 inch from the end taking care that the slide does not touch the skin. Place 
the end of a second slide against the surface of the first an angle of 30-40 and draw it 
against the drop of blood, push the spreader slide back along the other. The blood will 
follow and then smears should be made.  The film may be allowed to dry in the air. 
Leishman's stain is added, and after 2 mts double the quantity of distilled water are added 
to the stain and waited for 7-10 mts. Then the stain is washed in the tap water and slide 
dried in air and viewed under oil immersion.
The mature red corpuscle appears greenish yellow in unstained preparations and is 
roughly circular  in  shape  and  seen  on  edge  as  biconcave  disc.  Cells with  reduced 
concentration of heamoglobin are called hypochromic which may be so extensive that only 
a narrow rim of haemoglobin is left around the periphery. There cells are called pessary 
cells.
Spherocyte are small darkly staining cells or ring. Burr cells are mature red cells 
which possess one or more spiky projecting on their periphery seen in microangiopathic 
haemolytic anaemia.
SGOT ESTIMATION
Sample Collection, Storage and Stability
Although serum is preferred, plasma can be used. Anticoagulants such as heparin 
and EDTA can be used. Blood samples may be collected any time, although morning 
samples are preferred.
Samples with any visible hemolysis are not acceptable. Samples are stable for a 
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week at  2-8 C  and  for  one  month  at  10C  samples should  be  brought  to  room 
temperature prior to use.
Reagents
1. Aspartate/Buffer
1A. NADH/MDH/LDH
2. Alpha-Ketoglutarate
Preparation of working solutions
Allow the reagents to attain the room temperature.
Solution (1): Quantitatively transfer the contents of  Via 1A into bottle 1.  Mix until 
completely dissolved.
Solution (2): Dissolve the contents of bottle 2 with 14 ml of distilled water.
Preparation of daily working solutions
Allow the solutions (1) and (2) to attain the room temperature.
The daily working solution should be prepared freshly according to the need in the 
proportions given below:
Solution (1): 3.0 ml
Solution (2): 0.3 ml
Mix thoroughly, use within 8 hours of preparation - store at 2-8C.
Storage and stability of Reagents
Expiry date of reagents stored at 2-8C are
Solution (1): for 3 months
Solution (2): for 4 months
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Procedure
The samples and the daily working solution should be at the room temperature 
prior to use. The following general system parameter are used.
Reaction Type : Kinetic
Wavelength : 340 mm
Flowcell Temp : 37C
Delay Time : 60 Sec
No. of Readings : 4
Interval : 30 Sec
Sample Volume : 100 Ml
Reagent Volume : 1.0 ml
Pathlength : 1 cm
Factor : 1749
Zero setting with : Distilled water
Procedure limitations
• Haemolysis of sample can produce a significant positive error as red cells contain 
large amounts of GOT (AST).
• Samples with very high GOT activity cause an excessive consumption of NADH, 
resulting in a very low initial absorbance. When this occurs, the assay should be 
repeated with a diluted sample.
• Linearity of the method is upto 400 IU/L for higher values, dilute the sample 
suitably with 0.9% saline and repeat the assay. Apply proper dilution factor to 
calculate the final results.
Normal Values
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Upto 40 IU/L (37C)
SGPT ESTIMATION
Sample
Although serum is preferred, plasma can also be used with anticoagulants such as 
heparin or EDTA.
Morning samples are preferred. Serum or plasma GPT determination should be 
carried out on the same day as far as possible.
Samples are stable for about 3 days when stored tightly capped at 2-8C or for 
two weeks at - 10C.
Avoid using haemolysed or grossly contaminated samples. The samples should be 
brought to room temperature prior to use.
Reagents
1. Alanine / Buffer
2. NADH/LDH
3. Alpha - Ketoglutarate
Preparation of working solutions, storage and stability of reagents, procedure & 
procedure limitation.
Same as that for SGOT.
Normal values
Upto 40 IU/L (37C)
LDH ESTIMATION
Sample
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Although serum is preferred, plasma can be used only if heparin or EDTA is used 
as an anticoagulant. Avoid using hemolysed and grossly contaminated samples.
Serum or plasma should be separated from the blood sample as early as possible.
Serum or plasma can be used stored at 2-8C for one week.
Reagents
1. NADH
1A. Buffer
2. Pyruvate
Preparation of working solutions
Allow the reagents to attain the room temperature.  The  Ames Autopak LDH 
reagent  kit contains three  bottles/vials each  of  reagent  1  & 1A and  one  bottle of  
reagent 2.
Solution (1): Transfer a small amount of the contents of one bottle (1A) into one bottle 
(1). Mix gently to dissolve and transfer the solution back to bottle 
(1A). Rinse bottle (1) with solution in bottle (1A).
Reagent (2): Ready for use
Preparation of Daily working solutions
Allow the solution (1) and reagent (2) to attain the room temperature.
The daily working solution should be prepared fresh according to the need. Mix 
10 volumes of solution (1) with 1 volume of reagent (2) to obtain daily working solution.
Storage and stability of the Reagents
Expiry date of reagents stored at 2-8C is indicated on the box label.
Solution (1) is stable for six weeks at 2-8C Reagent (2) is stable at 2-8C until the end of 
expiry date on the table.
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Procedure
The  samples  and  the  daily  working  solution  should  be  brought  to  room 
temperature prior to use. The general system parameters are
Reaction Type : Kinetic
Wavelength : 340mm
Flow cell temperature : 37C
Delay time : 60 Sec
No. of Readings : 4
Interval : 30 Sec
Sample Volume : 30 μl
Reagent Volume : 1.0 ml
Pathlength : 1 cm
Factor : 5520
Zero setting with : Distilled water
Procedure limitations
Plasma can be used only if heparin or EDTA is used as an anticoagulant Citrate 
and oxalate interfere with the test and hence should not be used.
Do not use haemolysed samples as haemolysis may give falsely elevated results.
The method is linear upto 1000 IU/L. For higher values, dilute the sample suitably 
with 0.9% saline and repeat the assay. Apply proper dilution factor to calculate the final 
results.
Normal Values
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Upto 600 IU/L (37C)
SERUM BILIRUBIN ESTIMATION
Methods of detecting and estimating Bilirubin in serum are based on the formation 
of  the purple compound when bilirubin reacts with the diazo reagent introduced by 
vanden Berg.
Reagents
1. Absolute method
2. Diazo reagent prepared freshly by adding 0.3 ml of solution B to 10 ml of solution 
A.
a. Solution A
Dissolve 1 gm of sulphuric acid in 15 ml concentrated HC1 and make it to i liter 
with distilled water.
b. Solution B
- 0.5% sodium nitrite in water prepared at frequent intervals.
- Prepare a solution containing 10 mgm/100ml of chloroform. It may be 
necessary to reflex the mixture gently to dissolve the bilirubin.
Technique
Wash 0.2 ml of serum into 5.4 ml of 0.9% saline. For values above 15 mgms/0.1 
ml serum in 5.5 ml water may be taken serum 0.2, 5.6 ml divided into 4 parts of 1.4 ml 
each.
Total Bilirubin Direct Bilirubin
Test Control Test Control
Dilute Screen 1.4 ml 1.4 ml 1.4 ml 1.4 ml
UDBA - 0.35 ml - 0.35 ml
Diazo reagent 0.35 - 0.35 -
Water - - 1.75 1.75
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Methanol 1.75 1.75 - -
Let  it  stand  for  10  mts  read  against  water  blank  at  530mμ  photoelectric 
colorimeter.
Standardization
Mg/bilirubin per 100 ml 0-10-20-30-40
MI Standard solution 0.1 0.2 0.3 0.4 -
MI Chloroform 2.8 2.7 2.6 2.5 2.4
Diazo reagent 0.7 0.7 0.7 0.7 0.7
Methanol 3.5 3.5 3.5 3.5 3.5
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RESULTS
1. AGE CRITERIA
AGE
MILD PRE-
ECLAMPSIA
SEVERE PRE 
ECLAMPSIA
ECLAMPSIA
HELLP 
SYNDROME
<20 4 5.8% 9 9% 4 12.5% 2 13.33%
20-24 22 32.35% 35 35% 13 40.63% 7 46.66%
25-29 32 47.06% 38 38% 10 31.25% 4 26.66%
30 & 
above
10 14.71% 18 18% 5 15.62% 2 13.33%
According to the above table there were 15 cases of HELLP Syndrome, most cases 
were in 20-24 years of age.
2. GRAVIDA
GRAVIDA
MILD PRE-
ECLAMPSIA
SEVERE PRE 
ECLAMPSIA
ECLAMPSIA
HELLP 
SYNDROME
Primi 40 58.82% 52 52% 17 53.12% 6 40%
Multi 28 41.18% 48 48% 15 46.88% 9 60%
According  to  the  above  table,  HELLP  Syndrome,  shows  higher  incidence  in 
multigravida
45
05
10
15
20
25
30
35
40
45
50
PE
RC
EN
TA
G
E
MILD PE SEVERE PE ECLAMPISIA HELLP SYNDROME
FIG - 1 AGE CRITERIA
< 20 20 - 24 25-29 30 and Above
0
10
20
30
40
50
60
PE
RC
EN
TA
G
E
MILD PE SEVERE PE ECLAMPISIA HELLP SYNDROME
FIG - 2 GRAVIDA
PRIMI MULTI
46
3. PROTEINURIA
PROTEINURIA
MILD PRE-
ECLAMPSIA
SEVERE 
PRE 
ECLAMPSIA
ECLAMPSIA
HELLP 
SYNDROME
Nil - - - - - - - -
Trace 48 70.59% 4 4% 2 6.25% - -
+ 9 13.23% 36 36% 14 43.75% 1 6.66%
++ 9 13.23% 30 30% 8 25% 7 46.66%
+++ 2 2.94% 26 26% 6 18.75% 5 33.33%
++++ 0 - 4 4% 2 6.25% 2 13.33%
There were significant proteinuria in 90%  cases of HELLP Syndrome.
4. GESTATIONAL AGE
GEST
ATIO
NAL 
AGE
MILD PRE-
ECLAMPSIA
SEVERE PRE 
ECLAMPSIA ECLAMPSIA
HELLP 
SYNDROME
<20 - - - - - - - -
20-24 - - 1 1% - - - -
25-29 3 4.41% 11 11% 4 12.5% 2 13.33%
30-24 15 22.06% 36 36% 12 37.5% 7 46.66%
35-39 50 73.53% 51 51% 16 50% 5 33.33%
Deliver
ed
- - 1 1% - - 1 6.66%
According to the above table HELLP Syndrome was more common in 30-34 weeks.
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5. FUNDUS CHANGES
FUNDUS 
CHANGES 
MILDPRE 
ECLAMPSIA
SEVERE 
PREECLAMPSI
A
ECLAMPSIA HELLP SYNDROME
N ORMAL 67 98.53% 85 85% 27 84.37% 10 66.66%
GRADE I 1 1.47% 12 12% 3 9.38% 3 20%
GRADE II - - 3 3% 2 6.27% 2 13.33%
According to the above table, 67% cases of HELLP syndrome had normal fundus, 
33% cases had fundus changes
6. PLATELETS
PLATELETS
MILDPRE 
ECLAMPSIA
SEVERE 
PREECLAMPSI
A
ECLAMPSIA HELLP 
SYNDROME
CLASS I 
<50,000 - - - - - - - -
CLASS II 
50,000-1,00,
000
- - 2 2% 1 3.13% 3 20%
CLASS III 
1,00,000-1,5
0,000
25 36.76% 55 55% 15 46.97% 12 80%
NORMAL 
>1,50,000 43 63.24% 43 43% 16 50% - -
Isolated thrombocytopenia were found in preeclamptic Eclamptic group but in HELLP 
syndrome 20% cases belonged to class II and 80% cases to class III
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7. LIVER ENZYMES (ELEVATED)
LIVER 
ENZYMES 
(ELEVATED)
MILD PRE - 
ECLAMPSIA
SEVERE 
PRE - 
ECLAMPSIA
ECLAMPSIA HELLP SYNDROME 
SGOT 5 7.35% 16 16% 8 25% 15 100%
SGPT 3 4.41% 16 16% 6 18.75% 15 100%
LDH 3 4.41% 13 13% 5 15.63% 15 100%
Isolated elevation of liver enzymes found in Preeclamptic - Eclamptic group but there 
was significant elevation of liver enzymes in HELLP syndrome.
8. MODE OF DELIVERY
MODE OF 
DELIVERY
MILD PRE - 
ECLAMPSIA
SEVERE 
PRE 
ECLAMPSIA
ECLAMPSIA HELLP SYNDROME
LN 38 55.88% 53 53% 9 28.12% 9 60%
FORCEPS 4 5.88% 2 2% 1 3.13% 1 6.66%
LSCS 20 29.4% 29 29% 18 56.25% 3 20%
EAC 6 8.82% 15 15% 4 12.5% 1 6.66%
CERVIPRIME 19 27.94% 26 26% 4 12.5% 3 20%
CAESAREAN 
HYSTEREC 
TOMY
- - 1 1% - - 1 6.66%
According to the above table 60% cases of  HELLP syndrome delivered by labour 
natural,  20% by LSCS,  6.7%  by EAC (Preterm termination),  6.7%  by caesarean 
hysterectomy.
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 9. MATERNAL OUTCOME
MATERNAL OUTCOME MILD PRE 
ECLAMPSIA 
SERVERE 
PRE 
ECLAMPSIA 
ECLAMPSIA HELLP 
SYNDROME
ABRUPTION 3 4.41% 6 6% 2 6.25% 2 13.33%
CEREBRAL EDEMA - - - - 4 12.5% 1 6.66%
ACUTE RENAL 
FAILURE 1 1.47% 3 3% - - 2 13.33%
HIE - - 1 1% 1 3.12% 1 6.66%
CARDIORESPIRATORY 
ARREST - - - - 1 3.12% 1 6.66%
PERIPARTUM 
CARDIOMYOPATHY - - 1 1% - - - -
PULMONARY EDEMA - - - - - - - -
According  to  the  above  table,  significant  maternal  morbidity  in  HELLP 
syndrome was due to abruption and acute renal failure.
10. PERINATAL OUTCOME
PERINATAL 
OUTCOME 
MILD PRE – 
ECLAMPSIA 
SEVERE PRE 
ECLAMPSIA
ECLAMPSIA HELLP 
SYNDROME 
IUD 10 14.7% 20 20% 5 15.62% 5 33.33%
TERM ALIVE 38 55.88% 34 
(1Twin)
34% 12 37.5% 4 
(1Twin)
26.66%
TERM EXPIRED - - 2 2% 1 3.13% - -
PRETERM 
ALIVE
15 22.05% 34 
(1Twin)
34% 9 28.13% 2 13.33%
PRETERM 
EXPIRED
3 4.41% 6 6% 5 15.62% 3 20%
IUGR ALIVE 2 2.94% 4 4% - - 2 13.33%
IUGR  EXPIRED - - 2 2% - - - -
According to the above table, significant perinatal mortality in HELLP syndrome was 
due to prematurity
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11. BIRTH WEIGHT
BIRTH 
WEIGHT 
(gms)
MILD PRE - 
ECLAMPSIA
SEVERE PRE – 
ECLAMPSIA
ECLAMPSIA HELLP 
SYNDROME 
<500 - - - - - - - -
500-999 2 2.94% 10 10% 2 6.25% 1 6.66%
1000-1499 10 14.70% 19 19% 4 12.5% 2 13.33%
1500-1999 11 16.18% 34 34% 8 25% 7 46.66%
2000 and 
above
45 66.18% 39 39% 18 56.25% 6 40%
 Out of 16 babies delivered by HELLP syndrome cases, 6 babies were > 2000 gms 
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HELLP SYNDROME
A. BLOOD PRESSURE
MILD 
PREECLAMPSIA
SEVERE 
PREECLAMPSIA
ECLAMPSIA
1 11 3
6.66% 73.33% 20%
HELLP syndrome was common is severe preeclamptic group 
B. GESTATIONAL AGE
GESTATIONAL AGE 
(WEEKS)
HELLP SYNDROME
< 20 - -
20-24 - -
25-29 2 13.33%
30-34 7 46.66%
35-39 5 33.33%
DELIVERED 1 6.66%
HELLP syndrome was common in 30-34 weeks gestation 
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C. ANALYSIS OF LIVER ENZYMES LEVELS IN HELLP SYNDROME
Liver enzymes 
levels 1U/L
SGOT SGPT
70-110 8 53.33% 8 53.33%
111-150 3 20% 3 20%
151-190 1 6.66% 1 6.66%
191-230 - - - -
231-270 2 13.33% 2 13.33%
271-310 - - - -
311-350 - - - -
351-390 1 6.66% 1 6.66%
391 & above - - - -
SGOT and SGPT levels in HELLP syndrome were found mostly in the range 70-110 
IU/L
D. LDH
601-620 1U/
L
621-640 1U/
L
641-660 1U/
L
661-680 IU/
L
6810700 
IU/L
Above 700 
IU/L
3 4 2 3 3 -
20% 26.66% 13.33% 20% 20% -
LDH  levels mostly in the range 621 - 640 1U/L
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E. CORRELATION BETWEEN PLATELETS AND LIVER EZYMES IN 
CLASS II HELLP SYNDROME
S.No. PLATELETS LDH IU/L SGOT IU/L SGPT IU/L
1. 80,000 684 261 265
2. 70,000 692 182 186
3. 75,000 686 254 256
There is inverse correlation between platelets and liver enzymes in class II HELLP 
syndrome.
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Fig.E CORRELATION BETWEEN PLATELETS AND LDH IN CLASS II HELLP SYNDROME
64,000
66,000
68,000
70,000
72,000
74,000
76,000
78,000
80,000
82,000
80,000 70,000 75,000
680
682
684
686
688
690
692
694
PLATELETS LDH
CORRELATION BETWEEN PLATELETS AND SGOT IN CLASS II HELLP SYNDROME
64,000
66,000
68,000
70,000
72,000
74,000
76,000
78,000
80,000
82,000
80,000 70,000 75,000
0
50
100
150
200
250
300
PLATELETS SGOT
62
F. CORRELATION BETWEEN PLATELETS AND LIVER ENZYMES IN 
CLASS III HELLP SYNDROME
S.No. Platelets SGOT IU/L SG PT IU/L LDH 1U/L
1. 1.2 76 78 611
2. 1.05 116 118 672
3. 1.05 362 381 674
4. 1.15 152 148 668
5. 1.05 94 90 611
6. 1.15 86 88 608
7. 1.2 124 128 652
8. 1.05 81 84 632
9. 1.1 84 86 626
10. 1.15 86 84 624
11. 1.15 82 86 648
12. 1.15 92 96 632
There is inverse correlation between liver enzymes level and platelet count in 
class III HELLP syndrome.
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FIG. F. CORRELATION BETWEEN PLATELETS AND LDH IN CLASS III HELLP 
SYNDROME
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G. TREATMENT REGIMEN
ANTI HYPERTENSIVES + 
MgSO4 REGIMEN
ANTIHYPERTENSIVES ONLY
10 5
66.66% 33.33%
H. ADMISSION - DELIVERY INTERVAL IN HELLP SYNDROME 
< 6 hrs 6 - 10 hrs 11 -15 hrs DELIVERED 
OUTSIDE
1 5 8 1
6.66% 33.33% 53.33% 6.66%
In all cases of HELLP syndrome, Admission Delivery interval was < 15 hrs
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I   ANALYSIS OF MATERNAL MORTALITY
a. AGE
< 20 20-24 25-29 30  and above
- 2 1 -
- 66.66% 33.33% -
b. GRAVIDA
All cases were primigravidae
c. BLOOD PRESSURE
MILD PREECLAMPSIA SEVERE PRE 
ECLAMPSIA
ECLAMPISA
- 2 1
- 66.66% 33.33%
d. GESTATIONAL AGE
All cases were in 34 weeks gestation 
e. PROTEINURIA
++ +++ ++++
1 1 1
33.33% 33.33% 33.33%
f. PLATELETS COUNT
CLASS I < 50,000 CLASS II 50,000 - 
1,00,000
CLASS III 1,00,000 - 
1,50,000
- 2 1
- 66.6% 33.33%
g. LDH
All cases were in between 671-690 IU/L
h. SGPT & SGOT
231-270 (IU/L) 351-390 (IU/L)
2 1
66.66% 33.33%
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i. MODE OF DELIVERY
FORCEPS L.S.C.S CAESAREAN 
HYSTERECTOMY
1 1 1
33.33% 33.33% 33.33%
j. ADMISSION-DELIVERY-DEATH INTERVAL
24 hrs 48 hrs
2 1
66.66% 33.33%
k. MATERNAL MORTALITY - CAUSES 
ACUTE RENAL 
FAILURE
ABRUPTION, ACUTE 
RENAL FAILURE
ABRUPTION, 
CARDIO 
RESPIRATORY 
ARREST
1 1 1
33.33% 33.33% 33.33%
According to Table a-k, there were 3 cases of death in HELLP syndrome giving 
rise to maternal mortality rate of 20%. All cases were PRIMI between 20-25 years of 
age,  mostly in severe preclampsia at  34  weeks gestation.  All cases had  significant 
proteinuria, delivered within 12 hrs of admission. Most common causes of death were 
abruption and acute renal failure.
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POSTPARTUM LEVEL OF PLATELETS & LIVER 
ENZYMES IN HELLP SYNDROME
CASES PLATELETS Lakhs . Cumm SGOT IU/L SGPT IU/L LDH IU/L
CASE - 1
Admission 1.2 76 78 611
PP Day 2 1.8 32 28 394
CASE – 2
Admission 1.05 116 118 672
PP Day 3 1.75 22 28 391
CASE – 3
Admission 1.15 152 148 668
PP Day 3 1.75 24 32 374
CASE – 4
Admission 70,000 182 186 692
PP Day 4 1.6 26 30 380
CASE – 5
Admission 1.05 94 90 611
PP Day 3 1.75 22 24 297
CASE 6
Admission 1.15 86 88 608
PP Day 2 2.25 22 26 194
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CASE 7
Admission 1.2 124 128 652
PP Day 2 2.25 28 22 254
CASE – 8
Admission 1.05 81 84 632
PP Day 3 1.95 24 26 248
CASE 9
Admission 1.1 84 86 626
PP Day 3 1.95 28 24 236
CASE - 10
Admission 1.15 86 84 624
PP Day 2 1.85 22 20 238
CASE -11
Admission 1.15 82 86 648
PP Day 2 2.25 24 22 234
CASE - 12
Admission 1.15 92 96 632
PP Day 3 2.25 22 26 248
In all cases of HELLP syndrome, platelets count and liver enzymes returned to normal 
limits within 4th postpartum day.
CONSOLIDATED ANALYSIS OF THE STUDY
70
STUDY
MILD PE SEVERE PE ECLAMPSIA
P M P M P M HELLP SYNDROME
Total No. of cases 40 28 52 48 17 15 15
Proteinuria All All All All All All All
Fundus Changes 1 - 9 6 5 - 5
Low plateletcount 14 11 31 26 9 7 All
Evidence of 
haemolysis - 1 5 6 1 2 15
Elevated liver enzymes 1 4 9 7 5 3 15
Mode of Delivery 
LN 22 16 25 28 3 6 9
Forceps 2 2 1 1 - 1 1
LSCS 13 7 17 12 13 5 3
EAC 3 3 8 7 1 3 1
Cerviprime 15 4 18 8 2 2 3
Caesarean 
Hysterectomy - - 1 - - - 1
Fetal outcome 
IUD 6 4 10 10 5 - 5
Term Alive 21 17 19 15 8 4 4
Term Expired - - - 2 - 1 -
Preterm Alive 10 5 19 15 3 6 2
Preterm Expired 2 1 3 3 1 4 3
FGR alive 1 1 1 3 - - 2
FGR Expired - - 1 1 - - -
Maternal outcome 
Abruption 1 2 4 2 2 - 2
ARF 1 - 3 - - - 2
HIE - - 1 - - 1 1
Cerebral edema - - - - 1 3 1
Peripartum 
cardiomyopathy - - 1 - - - -
Cardiorespiratory arrest - - - - 1 - 1
Pulmonary edema - - - - - - -
 HELLP 
SYNDRO
ME 
 Alive - 1 3 6 - 2 12
Expired - - 2 - 1 - 3
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CONSOLIDATED INFERENCE OF THE STUDY
Total no. of cases studied : 200
Proteinuria : All (100%)
Fundus changes : 21 (10.5%)
Low platelets count : 98 (49%)
Elevated liver enzymes  : 29 (14.5%)
Evidence of haemolysis : 15 (7.5%)
MODE OF DELIVERY
LN : 100 (50%)
Forceps : 7 (3.5%)
LSCS : 67 (33.5%)
EAC : 25 (12.5%)
Cerviprime                    : 49 (24.5%)
Caesarean hysterectomy                     :        1 ( 0.5%)
MATERNAL OUTCOME
Abruption : 11 (5.5%)
Acute Renal failure : 4 (2%)
HIE : 2 (1%)
Cerebral edema : 4 (2%)
Cardio respiratory arrest : 1 (0.5%)
Peripartum Cardiomyopathy : 1 (0.5%)
Pulmonary edema : Nil
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PERINATAL OUTCOME
IUD : 35 (17.5%)
Term Alive            : 84 (42%)
Term Expired   : 3 (1.5%)
Preterm Alive    : 58 (29%)
Preterm Expired : 14 (7%)
IUGR Alive : 6 (3%)
IUGR  Expired  : 2 (1%)
Mild Preeclampsia : 68 (34%)
Primi gravida : 40
Multigravida : 28
Severe Preeclampsia : 100 (50%)
Primigravida : 52
Multigravida : 48
Eclampsia : 32 (16%)
AP Eclampsia : 24
Primi gravida : 13
Multi gravida : 11
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IP Eclampsia : 3
Primigravida : 1
 Multigravida : 2
PP Eclampsia                                                :            5
Primi Gravida : 3
Multi gravida : 2
HELLP SYNDROME : 15 (7.5%)
MATERNAL MORTALITY 
IN HELLP SYNDROME                      : 3 (20%)
PERINATAL MORTALITY 
IN HELLP SYNDROME               : 8 (53.33%)
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GOVERNMENT R.S. R.M. HOSPITAL
STATISTICS OF PRE ECLAMPSIA (MILD & SEVERE) AND ECLAMPSIA
 - 10 YEARS STUDY
Year
Total No 
Deliveries
Mild 
Preeclampsia
Severe 
Preeclampsia
Eclampsia
No. % No. % No. %
1996 10508 356 3.39 55 0.52 59 0.60
1997 10215 347 3.40 73 0.71 90 0.88
1998 10224 487 4.76 103 1.01 92 0.90
1999 10486 517 4.90 10.7 1.02 89 0.85
2000 12333 513 4.16 99 0.80 113 0.92
2001 12793 440 3.44 117 0.91 84 0.66
2002 12562 797 6.34 80 0.64 79 0.63
2003 14264 749 5.25 127 0.90 78 0.55
2004 14539 769 5.30 114 0.78 66 0.45
2005 14928 676 4.53 89 0.60 67 0.45
2006 till 
July 1st
7027 495 7.04 70 1.00 26 0.37
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0
1
2
3
4
5
6
7
8
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 - TILL
JULY IST
PE
R
C
EN
TA
G
E
76
R.S.R.M. STATISTICS OF SEVERE PREECLAMPSIA - 10 YEARS STUDY
0
0.2
0.4
0.6
0.8
1
1.2
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 (Till 1st
July)
YEARS
PE
R
C
EN
TA
G
E
77
R.S.R.M. STATISTICS OF ECLAMPSIA - 10 YEARS STUDY
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 (Till 1st
July)
YEARS
PE
R
C
EN
TA
G
E
78
DISCUSSION
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DISCUSSION
A study of 200 cases of preeclampsia -eclampsia was undertaken during the year 
2005-2006 to identify all the patients with HELLP Syndrome. Of these 68 cases belonged 
to mild preeclampsia (34%), 100 cases belonged to severe preeclampsia (50%) and 32 
cases belonged to eclampsia (16%).
Incidence 
James N.Martin 4-12%
B.E. Reubnoff 12-13.6%
Sibai 1986 9.7%
Sibai & Mohammed 1993 18.9%
My study 7.5%
The wide range of incidence can be attributed to the remarkable variability of the 
diagnostic criteria of the syndrome. In addition, these incidence rates cannot be considered 
for general population since they are reported from tertiary referral centres 
Age
University of Tennessee, Memphis 24.4 years
English literature 24.9 years
My study 24.07 years
Gravida
B.E. Reubinoff (1990) Multipara
My study Multipara (60%)
Incidence  of  HELLP  Syndrome  in  multigravida  (60%)  is  more  than  in 
primigravida (40%) 
Socioeconomic status 
All cases were unbooked and of low socioeconomic status probably because our 
institution caters of mainly to economically deprived strata of society.
Gestational age
The  average,  gestational age at  presentation  is 33.8  weeks,  70% of  HELLP 
Syndrome patients manifest before labour, while 30% manifest after delivery. According 
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to Sibai 82% cases developed HELLP syndrome at <37 weeks. According to my study 
average gestational age at presentation is 33.86 weeks, of which 93.33% cases of HELLP 
syndrome manifest antepartum.
Clinical Symptoms & Signs
The frequent symptom is epigastric pain and /or right upper quadrant pain (90%) 
accompanied by nausea and vomiting. Headache may be present in 50% cases. In my 
study 50% cases had right upper quadrant pain associated with nausea and vomiting, rest 
of the patients (50%) had right upper quadrant pain and headache 
Blood pressure
Mild Pre 
eclampsia
Severe pre 
eclampsia
Eclampsia
Sibai et al - 30% 10%
B.E. Reubinoff 
1991
- 67% -
My study 6.66% 73.33% 20%
According to my study,  6.66% cases of  HELLP syndrome belonged to  mild 
preeclampsia  group,  73.33%  to  severe  preeclampsia  group  and  20%  belonged  to 
eclampsia group. Surprisingly 1.47% of mild preeclamptic patients also developed HELLP 
Syndrome, indicating that HELLP Syndrome can also occur in mild preeclampsia patients 
(Dewhurst).
The difference between our results could be attributed to difference in the population 
studied (  a large percentage of referred patients at one centre) and to differences in 
diagnostic criteria for HELLP Syndrome. The stressing factor here is, HELLP Syndrome 
should be anticipated even in the absence of hypertension and /or proteinuria.
Proteinuria
Urine analysis showed proteinuria of more than 2+ in 93.33% cases of  HELLP 
Syndrome. It should be emphasized that 15% of HELLP Syndrome patients present with 
neither hypertension nor significant proteinuria (B.E. Reubinoff et al) In my study 6.66% 
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patients had 1+ poteinuria, 46.66% had 2+ proteinuria, 33.33% had 3 + proteinuria and 
13.33% had 4+ proteinuria.
According to Sibai, some women with HELLP Syndrome however hypertension 
and proteinuria may be absent or slight. Thus it is imperative that all health care providers 
become knowledgeable about clinical signs & symptoms that might herald the onset of 
HELLP Syndrome.
Platelets levels in HELLP Syndrome
Class I Class II Class III
Martin 1990 1.09% 28% 71%
My study - 20% 80%
The  definition of  abnormal  level varies among different  studies.  Severity of 
HELLP Syndrome is reflected in its laboratory parameters and not in the usual clinical 
parameters like blood pressure and proteinuria.
Haemolysis  
Although  microangiopathic  hemolytic  anemia  underlies  HELLP  Syndrome, 
paradoxically most patients are not anemic when first admitted to the hospital. In my study 
all 15 cases had hemolytic blood picture with haemoglobin ranging between 7.8 gms - 10 
gms.
Liver enzymes 
According to B.E. Reubinoff et al., type of enzymes and definition of abnormal 
level also varies among different studies. There is direct correlation between the degree of 
thrombocytopenia and measures of  liver dysfunction.  An inverse correlation between 
platelets and LDH concentration was seen in both classes of HELLP Syndrome. Serum 
concentration of SGOT generally paralleled lactate dehydrogenase during the course of 
HELLP Syndrome. In my study there is inverse correlation between platelets and LDH in 
both classes of HELLP Syndrome.
Fundus Changes 
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In my study 5 cases of HELLP Syndrome had evidence of vasospasm and disc 
hyperemia at fundus examination (33.33%)
Treatment regimen 
66.66% cases were started on MgSO4 regimen in addition to antihypertensive, 
while 33.33% cases were in antihypertensive only.
Mode of delivery
According to Sibai (1999), caesarean delivery rate is high with HELLP Syndrome 
especially when pregnancy is less than 34 weeks of gestation (68%). In pregnancies less 
than 30 weeks of gestation caesarean section rate is 87%. According to my study, 60% 
cases of HELLP Syndrome delivered by Labour natural, 20% by LSCS 6.7% by EAC 
(Preterm termination), 6.7% by caesarean hysterectomy.
Admission Delivery interval
According to  Martin  (1990)  Length  of  time between hospital admission and 
delivery with a mean of 15.6 hours. According to my study admission delivery interval 
was less than 15 hours in all cases of HELLP Syndrome.
Maternal Outcome 
Though coagulapathy has been mentioned as the most common complication of 
HELLP Syndrome, in my study all parameters like bleeding time (B.T),  Clotting time 
(C.T),  serum fibrinogen were normal. This may be due to non sensitive parameters to 
detect DIC. More sensitive parameters like antithrombin IV, factor VIII and D-dimer may 
be needed to detect DIC.
Abruption Renal failure Cerebral edema Peri partum 
Cardiomyopathy
Sibai 1999 20% 8% 1% 6%
My study 13.33% 13.33% 6.66% -
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Maternal Mortality
According to sibai  (1999) incidence of maternal mortality is as high as 24%. In 
my study, there were 3 cases of maternal death giving rise to maternal mortality rate of 
20%, of these 1 case was due to cardio respiratory arrest and abruption 33.33%, 1 case 
was due to abruption and acute renal failure (33.33%) and 1 case was due to acute renal 
failure 33.33%.
Analysis of maternal mortality
Age-All cases were in 20-25 years of age.
Gravida - all cases were primigravida.
Blood pressure-66.66% cases belong to severe preeclampsia group, 33.33% cases belong 
to Eclampsia group. 
Gestational age - All 3 cases were in 34 weeks gestation.
Proteinuria - All 3 patients had > 2+proteinuria. 
Platelet count - 66.66% cases belong to class II HELLP Syndrome, 33.33% cases belong 
to class III HELLP Syndrome.
Liver enzymes - SGOT, SGPT and LDH were significantly elevated in all 3 cases.
Mode of delivery - 1 case (33.33%) delivered by outlet forceps with episiotomy, 1 case 
(33.33%) delivered by LSCS and 1 case (33.33%) underwent caesarean hysterectomy.
Admission - delivery death interval - 1 day for 2 cases (66.66%) and 2 days for 1 case 
(33.33%) In spite of early delivery there was 3 deaths in my study, probably due to late 
referral.
Perinatal outcome
According to Sibai perinatal mortality is 30-40% primarily because of prematurity. 
There is a significant trend for advanced form of HELLP Syndrome (Class I & Class II) 
to appear at earlier gestational age. According to my study perinatal mortality is 53.33% 
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primarily of prematurity.
Sibai 1999            30-40%
My study             53.33%
Birth weight of the baby
According to English literature, average weight of the new born is 1524-1898 gms 
and 30% were small for gestational age. According to my study 1 baby (6.66%) was 
500-999 gms,2 babies (13.33) were 1000-1499 gms, 7 babies (46.66%) were 1500-1999 
gms and 6 babies (40%) were 2000 grams and above.
Post partum period
Lowest platelet count did not predict peak values of aspartate aminotransferase or lactate 
dehydrogenase. The degree of abnormality of platelet counts, AST and LDH did not 
perspectively and accurately predict time of recovery. According to text, at 5-7 days after 
delivery, platelet count were above 1,00,000/cumm in 85-96% of cases, AST were below 
70 IU/L in 85-96% and LDH values were below 600 IU/L in 76-89%. In my study all 
cases for platelet count and liver enzymes reverted to normal levels by  4th post partum 
day.
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SUMMARY
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SUMMARY
A prospective analytical study of 200 cases of preeclamptic -eclamptic group was 
undertaken  during  the  year  2005-2006  to  identify  the  patients  at  risk  of  HELLP 
Syndrome.
Incidence of HELLP Syndrome as per this study is 7.5%
Multigravida has a slightly higher incidence (60%) than primigravida (40%).
Mean maternal age of HELLP Syndrome as per this study is 24.07 years.
Average gestational age, that HELLP Syndrome presents is 33.86 weeks.
Most cases of HELLP Syndrome occurred antepartum (93.33%) 
Most cases of HELLP Syndrome belonged to severe preeclamptic group (73.33%)
93.33% cases of HELLP Syndrome had > or = 2+ proteinuria.
20% cases of HELLP Syndrome belonged to class II and 80% cases belonged to
class III HELLP Syndrome. 
Mode of delivery.
60% cases of HELLP Syndrome delivered by labour natural, 20% by LSCS, 6.7% by 
caesarean hysterectomy 6.7% cases were terminated by extra amniotic catheter before 
term.
Admission delivery interval was <15 hours in all cases.
Significant maternal morbidity in HELLP Syndrome was due to abruption(13.33%) and 
acute renal failure (13.33%).
Significant  pertinatal  morbidity  and  mortality  in  HELLP  Syndrome  was  due  to 
prematurity.
Maternal mortality rate in HELLP Syndrome is 20% Perinatal Mortality rate in HELLP 
Syndrome is 53.33%
In all cases, the laboratory parameters returned to normal limits within 4th postpartum day.
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CONCLUSION
The question of whether HELLP Syndrome exists as a distrint entity or not is a 
part of a spectrum of pregnancy complications, which have common liver dysfunction, 
haemolysis  and  thrombocytopenia  has  long  been  a  source  of  speculation  among 
obstetricians and physicians. However,  the importance of  this collection of  signs and 
symptoms lies not in its name but rather in its associated high maternal and perinatal 
morbidity and mortality. Hence,
1. Patient with HELLP Syndrome warrants an emergency obstetric help.
2. HELLP  Syndrome  demands,  careful  and  close  evaluation  of  maternal  and 
neonatal parameters and should be given equal attention in decision making.
3. Prompt delivery is mandatory regardless of gestational age.
4. Successful management requires recognition, a timely intervention and to render 
optimal patient treatment.
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1. Name of the patient :
2. Age :
3. DOA :
4. D.O.D. :
5. Married :
6. Socio Economic Group :
7. Gravida :
8. Para :
9. Abortion :
10. L.M.P. :
11. EDD :
12. H/o. M.A. :
13. F/H HT :
Cardiac disease:
D.M :
14. Present illness :
a. Giddiness :
b. Oliguria :
c. Blurring in Vision :
98
d. Head Ache :
e. Epi gastric pain :
15. G/E
a. Anaemia :
b. Oedema :
c. Pulse :
d. BP :
16. O/E
a. Ascites :
b. Any overdistension :
c. Height of uterus :
d. Head engaged (or) not :
e. F.H. :
f. Amount of liquor :
g. Abnormal Presentation :
h. Complication Abruption :
17. Investigations
a. Daily weight :
b. Urine C & S :
c. Albumin deposit :
99
d  Fundus examination :
e. Blood Urea :
f. Sr.Uric Acid :
g. Sr.Creatinine :
h. Peripheral Smear :
i. anisocytosis :
ii. Poikilocytosis :
iii. Schistocytosis :
iv.Burr Cells :
v.Micro Spherocyte :
18. Serum Bilirubin :
             Total Bilirubin :
             Direct Bilirubin :
19. SGOT :
SGPT :
Sr. LDH :
20. Platelet count :
21. USG :
22. Outcome of delivery :
Mode of delivery :
100
a. Natural delivery : :
b. Forceps :
c. L.S.C.S. :
22. Baby Wt, Apgar
101
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MILD PREECLAMPSIA - PRIMI
Sl.
No.
Age Gestatio
nal age
(weeks)
Wt
. 
Kg
Urine 
Alb.
BP mm-
Hg
Fundus Blood 
Urea 
mg %
Sr. 
Creatini
ne
mg %
Serum 
Uric 
acid 
mg %
Platelet 
Count 
Lakhs / 
mm3
Peripheral 
Smear
Sr. Bilirubin mg % SG OT 
IU/L
SG PT 
IU/L
Sr. 
LDH
IU / L
Mode of delivery Baby Mater
nal 
Outco
me
Fetal 
Outc
ome
Total Direct Indirect L.N. Force 
ps
LSCS Sex Wt 
 kg
Apg 
1 mt
1. 19 36 49 + 140/100 Normal 16 0.6 4.1 1.75 NHBP 0.9 0.6 0.3 22 24 102 - - c M 2.7 8/10 Well Well
2. 22 34 52 Trace 150/90 Normal 18 0.6 3.5 1.05 NHBP 0.8 0.5 0.3 30 32 116  - - F 1.9 7/10 Well Well
3. 20 35 50 Trace 140/90 Normal 17 0.6 3.5 1.85 NHBP 0.8 0.6 0.2 30 28 122 c - - F 1.85 7/10 Well Well
4. 23 37 62 + 140/100 Normal 20 0.7 3.6 1.15 NHBP 0.9 0.7 0.2 26 24 147 - - c M 2.8 8/10 Well Well
5. 32 32 56 Trace 130/100 Normal 18 0.6 3.7 2.25 NHBP 0.9 0.6 0.3 28 30 98 EAC - - F 1.4 8/10 Well Well
6. 21 37 48 ++ 150/100 Normal 16 0.6 3.6 2.15 NHBP 0.9 0.6 0.3 24 28 91 - -  M 2.6 8/10 Abruptio
Well
Well
7. 26 38 64 Trace 140/100 Normal 22 0.6 3.5 1.25 NHBP 0.8 0.6 0.2 30 34 106 - - c M 3.5 8/10 Well Well
8. 25 34 56 Trace 130/100 Normal 20 0.6 3.3 2.05 NHBP 0.8 0.5 0.3 28 32 104  - - F 1.8 8/10 Well Well
9. 27 40 63 + 140/90 Normal 24 0.7 3.3 1.05 NHBP 0.9 0.6 0.3 20 22 96 c - - M 3.0 8/10 Well Well
10. 17 28 47 Trace 150/90 Normal 18 0.6 3.5 2.2 NHBP 0.9 0.7 0.2 73 75 607 EAC - - F 950 
gm
1/10 Well Expired
11. 25 40 61 ++ 150/100 Grade I 16 0.6 3.7 1.25 NHBP 0.8 0.6 0.2 22 24 126 - -  M 3.75 8/10 Well Well
12. 24 38 49 Trace 140/100 Normal 18 0.6 3.3 2.4 NHBP 0.9 0.6 0.3 26 22 137 c - - F 3.2 7/10 Well Well
13. 31 30 61 Trace 140/100 Normal 20 0.6 4.1 1.45 NHBP 0.8 0.6 0.2 28 24 143  - - M 1.2 2/10 Well Expired
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Sl.
No.
Age Gestatio
nal age
(weeks)
Wt
. 
Kg
Urine 
Alb.
BP mm-
Hg
Fundus Blood 
Urea 
mg %
Sr. 
Creatini
ne
mg %
Serum 
Uric 
acid 
mg %
Platelet 
Count 
Lakhs / 
mm3
Peripheral 
Smear
Sr. Bilirubin mg % SG OT 
IU/L
SG PT 
IU/L
Sr. 
LDH
IU / L
Mode of delivery Baby Mater
nal 
Outco
me
Fetal 
Outc
ome
Total Direct Indirect L.N. Force 
ps
LSCS Sex Wt 
 kg
Apg 
1 mt
14. 27 36 60 + 150/100 Normal 21 0.7 4.0 2.65 NHBP 0.8 0.5 0.3 22 20 127  - - F 2.3 7/10 Well Well
15. 23 35 57 Trace 150/90 Normal 19 0.6 3.5 1.95 NHBP 0.9 0.7 0.2 22 24 118  - - F 1.75 IUD Well Dead 
Born
16. 28 37 59 ++ 130/100 Normal 20 0.6 3.7 1.35 NHBP 0.8 0.5 0.3 30 26 116  - - F 1.9 7/10 Well Well
17. 22 34 56 Trace 140/100 Normal 22 0.6 3.3 1.75 NHBP 0.8 0.5 0.3 32 28 124  - - F 1.85 7/10 Well Well
18. 27 37 54 Trace 140/100 Normal 20 0.6 3.5 2.25 NHBP 0.9 0.6 0.3 30 34 134 - c - M 2.75 8/10 Well Well
19. 18 38 51 + 150/100 Normal 18 0.6 3.7 2.15 NHBP 0.9 0.7 0.2 32 34 147  - - M 2.2 IUD Well Dead 
Born
20. 20 37 49 + 140/90 Normal 18 0.6 3.3 1.95 NHBP 0.8 0.6 0.2 26 22 106 - -  M 2.6 8/10 Well Well
21. 29 38 56 Trace 150/90 Normal 20 0.6 3.3 1.25 NHBP 0.9 0.6 0.3 24 26 104 -  - M 2.75 7/10 Well Well
22. 27 32 56 Trace 150/100 Normal 20 0.6 3.5 1.85 NHBP 0.8 0.5 0.3 28 22 114 EAC - - F 1.45 IUD Well Dead 
Born
23. 32 38 64 ++ 140/100 Normal 18 0.6 3.1 2.25 NHBP 0.8 0.5 0.3 24 20 116 C - - F 3.1 8/10 Well Well
24. 25 32 57 Trace 130/100 Normal 22 0.7 3.7 1.35 NHBP 0.9 0.7 0.2 20 20 117  - - F 1.4 7/10 Well Well
25. 21 37 61 Trace 130/100 Normal 24 0.6 3.5 2.35 NHBP 0.9 0.6 0.3 22 26 126  - - M 2.3 IUD Well Dead 
Born
26. 26 40 58 Trace 140/90 Normal 22 0.7 3.3 2.45 NHBP 0.9 0.6 0.3 30 28 114 - -  M 3.8 8/10 Well Well
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Sl.
No.
Age Gestatio
nal age
(weeks)
Wt
. 
Kg
Urine 
Alb.
BP mm-
Hg
Fundus Blood 
Urea 
mg %
Sr. 
Creatini
ne
mg %
Serum 
Uric 
acid 
mg %
Platelet 
Count 
Lakhs / 
mm3
Peripheral 
Smear
Sr. Bilirubin mg % SG OT 
IU/L
SG PT 
IU/L
Sr. 
LDH
IU / L
Mode of delivery Baby Mater
nal 
Outco
me
Fetal 
Outc
ome
Total Direct Indirect L.N. Force 
ps
LSCS Sex Wt 
 kg
Apg 
1 mt
27. 22 30 53 Trace 150/90 Normal 18 0.6 4.1 1.15 NHBP 0.8 0.6 0.2 32 30 96  - - F 1.3 7/10 Well Well
28. 27 37 59 ++ 140/100 Normal 20 0.6 4.0 2.25 NHBP 0.8 0.6 0.2 30 24 98 - - C M 2.7 8/10 Well Well
29. 26 38 61 Trace 140/90 Normal 22 0.6 3.7 2.15 NHBP 0.8 0.5 0.3 32 22 134 C - - M 2.5 8/10 Well Well
30. 18 36 47 ++ 150/100 Normal 24 0.6 3.5 1.05 NHBP 0.9 0.6 0.3 34 30 146  - - M 2.1 IUD ARF 
Well
Dead 
Born
31. 25 34 53 Trace 150/90 Normal 18 0.6 3.7 2.05 NHBP 0.9 0.7 0.2 18 20 154  - - F 1.75 8/10 Well Well
32. 22 36 54 Trace 150/100 Normal 16 0.6 3.3 1.2 NHBP 0.9 0.7 0.2 20 22 152 - - C F 2.4 8/10 Well Well
33. 26 35 59 Trace 150/90 Normal 19 0.6 3.5 2.15 NHBP 0.9 0.6 0.3 24 20 150  - - F 2.0 8/10 Well Well
34. 23 36 60 + 140/90 Normal 17 0.6 4.0 2.35 NHBP 0.9 0.6 0.3 26 22 147 - -  M 2.3 8/10 Well Well
35. 28 34 61 Trace 140/100 Normal 16 0.6 4.1 2.45 NHBP 0.8 0.6 0.2 28 26 143  - - F 1.8 8/10 Well Well
36. 27 37 63 Trace 150/90 Normal 20 0.6 4.2 1.35 NHBP 0.8 0.5 0.3 30 24 137 C - - F 2.5 7/10 Well Well
37. 22 38 57 ++ 140/100 Normal 18 0.6 3.7 2.5 NHBP 0.8 0.5 0.3 24 22 135 - -  M 2.7 7/10 Well Well
38. 26 38 64 Trace 130/100 Normal 22 0.7 3.5 1.95 NHBP 0.8 0.6 0.2 28 26 126 C - - M 2.65 8/10 Well Well
39. 21 38 54 Trace 130/100 Normal 22 0.6 4.5 2.15 NHBP 0.9 0.6 0.3 22 24 126 - - c F 2.5 8/10 Well Well
40. 30 37 57 + 150/100 Normal 24 0.6 4.1 1.35 NHBP 0.8 0.6 0.2 28 26 114 - - c M 2.3 IUD Well Dead 
Born
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Sl.
No.
Age Gestatio
nal age
(Weeks)
Wt
. 
Kg
Urine 
Alb.
BP mm-
Hg
Fundus Blood 
Urea 
mg %
Sr. 
Creati
nine
mg%
Serum 
Uric 
acid 
mg%
Platelet 
Count 
Lakhs / 
mm3
Peripheral 
Smear
Sr. Bilirubin mg % SG OT 
IU/L
SG PT 
IU/L
Sr. 
LDH
IU / L
Mode of delivery Baby Maternal 
Outcome
Fetal 
Outcome
Total Direct Indirec
t
L.N. Force 
ps
LSC
S
Sex Wt kg Apg 
1 mt
1. 24 34 54 Trace 140/100 Normal 18 0.6 3.3 1.15 NHBP 0.9 0.6 0.3 26 28 191  - - F 1.95 7/10 Well Well
2. 26 37 59 Trace 140/100 Normal 19 0.6 3.1 1.65 NHBP 0.8 0.6 0.2 22 24 101  - - M 2.6 8/10 Well Well
3. 30 38 67 ++ 140/100 Normal 18 0.7 3.5 1.35 NHBP 0.9 0.7 0.2 24 20 171  - - M 2.6 8/10 Well Well
4. 23 30 60 Trace 140/100 Normal 20 0.6 3.7 1.85 NHBP 0.8 0.5 0.3 20 22 98  - - F 1.45 7/10 Well Well
5. 25 36 62 Trace 130/90 Normal 16 0.6 3.5 1.25 NHBP 0.8 0.5 0.3 19 24 106  - - M 2.2 8/10 Well Well
6. 27 35 59 Trace 140/90 Normal 18 0.6 4.0 1.95 NHBP 0.9 0.6 0.3 77 81 603 EAC - - M 2.05 IUD Abruptio
n Well
Dead 
born
7. 31 37 63 Trace 150/100 Normal 20 0.6 4.2 2.25 NHBP 0.8 0.6 0.2 24 22 167 - -  F 2.75 8/10 Well Well
8. 22 32 58 +++ 140/100 Normal 22 0.7 3.7 1.05 NHBP 0.8 0.5 0.3 26 22 154  - - M 1.4 7/10 Well Well
9. 26 38 54 Trace 150/90 Normal 20 0.6 3.5 2.15 NHBP 0.8 0.6 0.2 24 20 176 C - - F 2.9 8/10 Well Well
10. 28 40 62 Trace 150/100 Normal 24 0.7 3.5 2.05 NHBP 0.9 0.6 0.3 22 22 164 - - c M 3.2 9/10 Well Well
11. 31 38 49 Trace 140/90 Normal 18 0.6 3.3 2.15 NHBP 0.9 0.6 0.3 24 20 91  - - M 2.8 8/10 Well Well
12. 23 39 56 + 140/90 Normal 19 0.6 6.8 1.2 Schistocy
tes+
0.8 0.5 0.3 76 78 611 - -  F 3.1 8/10 Well Well
13. 24 37 47 Trace 140/100 Normal 16 0.6 3.5 1.95 NHBP 0.9 0.7 0.2 19 16 106 - -  F 3.9 8/10 Well Well
14. 28 36 57 Trace 150/90 Normal 20 0.6 3.3 1.85 NHBP 0.9 0.7 0.2 35 32 126 - c - F 3.0 8/10 Well Well
15. 22 37 59 Trace 140/100 Normal 18 0.6 3.7 2.15 NHBP 0.8 0.6 0.2 30 28 147 - -  F 2.9 8/10 Well Well
16. 27 36 60 Trace 150/100 Normal 20 0.6 3.5 1.25 NHBP 0.8 0.5 0.3 28 24 186  - - M 2.8 7/10 Well Well
17. 32 28 64 Trace 140/100 Normal 22 0.6 3.7 2.05 NHBP 0.8 0.5 0.3 28 26 192 EAC - - F 750 
gm
IUD Well Dead Born
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Sl.
No.
Age Gestatio
nal age
(Weeks)
Wt
. 
Kg
Urine 
Alb.
BP mm-
Hg
Fundus Blood 
Urea 
mg %
Sr. 
Creati
nine
mg%
Serum 
Uric 
acid 
mg%
Platelet 
Count 
Lakhs / 
mm3
Peripheral 
Smear
Sr. Bilirubin mg % SG OT 
IU/L
SG PT 
IU/L
Sr. 
LDH
IU / L
Mode of delivery Baby Maternal 
Outcome
Fetal 
Outcome
Total Direct Indirec
t
L.N. Force 
ps
LSC
S
Sex Wt kg Apg 
1 mt
18. 26 35 67 +++ 150/90 Normal 20 0.6 4.1 1.05 NHBP 0.8 0.6 0.2 71 28 176  - - M 1.8 8/10 Well Well
19. 29 38 69 Trace 140/90 Normal 18 0.6 3.7 2.25 NHBP 0.9 0.6 0.3 30 32 162  - - F 1.95 7/10 Well Well
20. 27 37 59 Trace 130/100 Normal 19 0.6 3.3 1.25 NHBP 0.9 0.6 0.3 30 32 147  - - M 2.5 IUD Well Dead Born
21. 26 32 62 Trace 140/100 Normal 18 0.6 3.5 2.45 NHBP 0.9 0.7 0.2 72 38 196  - - F 1.4 8/10 Well Well
22. 31 36 64 Trace 140/90 Normal 20 0.6 3.3 1.45 NHBP 0.8 0.6 0.2 22 24 118 c - - M 2.7 8/10 Well Well
23. 28 37 65 ++ 150/90 Normal 22 0.6 3.7 2.15 NHBP 0.8 0.5 0.3 20 24 126 - -  F 2.9 8/10 Abruptio
nWell
Well
24. 21 34 58 Trace 150/100 Normal 18 0.6 3.5 1.25 NHBP 0.9 0.7 0.2 22 26 114  - - M 1.45 IUD Well Dead 
Born
25. 29 38 67 Trace 140/100 Normal 20 0.6 4.0 2.25 NHBP 0.8 0.6 0.2 28 26 124  - - F 3.5 8/10 Well Well
26. 32 37 56 Trace 130/100 Normal 18 0.6 4.1 2.35 NHBP 0.8 0.5 0.3 24 28 136 -  - F 3.25 9/10 Well Well
27. 25 37 59 Trace 140/100 Normal 16 0.6 3.7 1.15 NHBP 0.9 0.6 0.3 30 24 134 - -  M 3.1 8/10 Well Well
28. 23 28 57 Trace 140/90 Normal 20 0.6 3.3 1.95 NHBP 0.9 0.6 0.3 32 24 138 EAC - - F 1.1 1/10 Well Expired
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Sl.
No.
Age Gestatio
nal age
(Weeks)
Wt
. 
Kg
Urine 
Alb.
BP mm-
Hg
Fundus Blood 
Urea 
mg%
Sr. 
Creati
nine
mg%
Serum 
Uric 
acid 
mg%
Platelet 
Count 
Lakhs / 
mm3
Peripher
al 
Smear
Sr. Bilirubin mg % SG 
OT 
IU/L
SG 
PT 
IU/L
Sr. 
LDH
IU / L
Mode of delivery Baby Maternal 
Outcome Fetal 
Outco
me
Total Direct Indirec
t
L.N. Force 
ps
LSCS Sex Wt kg Apg 
1 mt
1. 18 34 49 + 160/120 Normal 30 0.7 7.3 1.05 NHBP 0.9 0.6 0.3 33 31 191 - - C F 1.75 8/10 Well Well
2. 30 28 57 Trace 170/110 Normal 28 0.6 6.8 1.95 NHBP 0.9 0.6 0.3 81 87 182 EAC - - M 850 
gm
IUD Well Dead 
Born
3. 25 38 56 +++ 170/120 Normal 28 0.7 8.2 1.25 NHBP 1.0 0.7 0.3 30 28 171 - - C M 3.0 8/10 Well Well
4. 21 30 54 ++ 180/110 Normal 32 0.7 8.5 1.15 NHBP 0.8 0.6 0.2 26 28 162 EAC - - F 1.4 8/10 Well Well
5. 26 32 60 +++ 160/110 Grade I 20 0.6 6.2 1.05 Schisto
cytes+
0.8 0.6 0.2 116 118 672 C - - F 1.7 7/10 HIE Well Well
6. 27 37 62 + 160/120 Normal 30 0.6 9.0 1.85 NHBP 0.9 0.7 0.2 24 26 173 - -  M 2.7 8/10 Well Well
7. 19 28 50 +++ 160/120 Normal 26 0.6 7.8 1.1 NHBP 0.9 0.6 0.2 28 28 167 EAC - - F 950 
gm
IUD Well Dead 
Born
8. 22 39 61 + 160/110 Normal 26 0.7 8.2 1.25 NHBP 0.8 0.5 0.3 22 26 156 - -  F 3.5 8/10 Well Well
9. 31 32 56 ++ 170/110 Normal 28 0.6 8.4 1.95 NHBP 0.8 0.5 0.3 30 32 184 EAC - - M 1.45 8/10 Well Well
10. 23 34 66 ++++ 170/110 Grade I 31 0.9 8.6 80,000 Schisto
cytes+
2.3 1.5 0.8 261 265 684 -  - F 2.0 IUD ARF Expired Dead Born
11. 26 40 62 +++ 170/120 Normal 28 0.8 8.4 1.2 NHBP 0.9 0.7 0.2 39 36 192 - -  M 3.7 8/10 Well Well
12. 24 34 49 + 160/110 Normal 26 0.6 7.8 1.75 NHBP 0.9 0.6 0.3 24 22 116  - - M 1.5 IUD Well Dead 
Born
13. 32 28 61 ++ 160/110 Normal 24 0.6 7.6 1.15 NHBP 1.0 0.7 0.3 24 24 124 EAC - - F 750 IUD Abruption Dead 
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gm Well Born
14. 29 36 48 Trace 170/110 Grade I 28 0.6 7.7 2.25 NHBP 0.8 0.5 0.3 20 26 116 - - TWINS F 
F
1.6
1.7
8/10 Well Well
15. 17 38 45 + 170/110 Normal 30 0.7 7.5 1.05 NHBP 0.8 0.6 0.2 22 20 125 c - - M 2.6 8/10 Well Well
16. 28 34 63 +++ 170/120 Normal 30 0.6 7.3 2.15 NHBP 0.9 0.7 0.2 96 94 612 c - - F 1.7 8/10 Well Well
17. 23 36 55 ++++ 180/120 Grade I 28 0.6 7.5 2.05 NHBP 0.8 0.5 0.3 24 26 192  - - M 1.6 3/10 ARF Well
Expired
18. 25 36 64 + 160/110 Normal 28 0.6 7.1 1.35 NHBP 0.9 0.6 0.3 22 28 186 c - - F 1.8 8/10 Well Well
19. 31 32 56 ++ 160/110 Normal 26 0.6 8.0 1.4 NHBP 0.9 0.6 0.3 30 32 148  - - F 1.40 8/10 Well Well
20. 26 34 54 + 170/110 Normal 28 0.7 7.2 1.25 NHBP 0.9 0.7 0.2 32 30 168  - - M 1.9 IUD Peripartum 
Cardiom
yopath, 
GSH
Dead 
Born
21. 17 38 60 +++ 170/120 Normal 30 0.7 7.6 1.95 NHBP 0.9 0.6 0.3 82 86 184 - -  F 1.9 8/10 Abruption 
Well
Well
22. 20 37 46 + 160/110 Normal 26 0.6 8.2 1.15 NHBP 1.0 0.8 0.2 30 28 172 c - - M 2.2 8/10 Well Well
23. 27 28 62 ++++ 180/120 Grade I 24 0.6 7.3 1.3 NHBP 0.8 0.6 0.2 26 28 168 EAC - - M 600 
gm
IUD Well Dead 
Born
24. 22 30 49 ++ 160/110 Normal 30 0.6 8.8 1.85 NHBP 0.8 0.5 0.3 24 22 146  - - F 1.2 8/10 Well Well
25. 19 36 45 + 160/110 Normal 32 0.7 7.4 1.15 NHBP 0.9 0.7 0.2 20 24 172 - -  F 1.8 8/10 Well Well
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26. 28 32 61 +++ 170/110 Normal 28 0.6 9.0 2.25 NHBP 0.8 0.5 0.3 28 30 184  - - M 1.0 3/10 Well Expired
27. 30 37 54 + 160/120 Grade I 26 0.6 9.2 1.35 NHBP 0.9 0.6 0.3 28 28 176 c - - F 2.5 8/10 Well Well
28. 24 34 60 ++ 160/110 Normal 32 0.7 8.0 1.25 NHBP 0.9 0.6 0.3 24 22 124  - - M 1.7 8/10 Well Well
29. 25 34 51 ++ 150/110 Normal 30 1.0 7.8 1.05 Fragm
ented 
RBC's
0.8 0.6 0.2 362 381 674 - - LSCS 
Hysterect
omy
M 1.15 8/10 Abruption
ARF 
Expired
Well
30. 26 38 62 + 150/110 Normal 28 0.6 8.2 1.75 NHBP 0.9 0.7 0.2 22 20 116 - -  M 3.1 7/10 Well Well
31. 22 34 51 ++ 160/110 Normal 28 0.7 7.8 1.05 NHBP 0.9 0.6 0.3 24 22 120 c - - F 1.5 3/10 Well Expired
32. 27 39 64 + 170/110 Normal 26 0.6 7.6 1.85 NHBP 1.0 0.7 0.3 30 28 162 - -  F 2.7 6/10 Well Well
33. 31 28 61 + 160/110 Normal 30 0.8 7.3 1.35 NHBP 0.8 0.5 0.3 28 30 172 EAC - - F 700 
gm
IUD Well Dead 
Born
34. 21 40 49 +++ 170/110 Grade I 24 0.6 8.0 1.95 NHBP 0.9 0.6 0.3 30 32 184 - - c M 3.2 6/10 Well Well
35. 28 32 60 ++ 170/110 Normal 22 0.6 7.1 1.95 NHBP 1.0 0.8 0.2 30 28 176  - - F 1.5 IUD Well Dead 
Born
36. 21 40 47 + 150/120 Normal 24 0.7 9.0 1.05 NHBP 0.8 0.5 0.3 28 30 124 c - - M 3.1 8/10 Well Well
37. 18 PN 51 +++ 150/120 Grade II 23 0.7 6.8 1.15 Burcell
s
0.9 0.6 0.3 152 148 668  
Outsid
e
- - F 2.1 8/10 Well Well
38. 25 36 52 +++ 160/110 Normal 28 0.6 8.2 2.05 NHBP 0.8 0.5 0.3 22 24 118 c - - M 2.2 8/10 Well Well
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39. 31 36 66 +++ 170/110 Normal 28 0.7 7.3 1.15 NHBP 0.9 0.6 0.3 36 34 194 - -  M 1.9 8/10 Well Well
40. 22 34 54 ++ 170/120 Normal 27 0.6 7.6 1.95 NHBP 0.8 0.6 0.2 33 32 176  - - F 1.75 8/10 Well Well
41. 25 37 63 +++ 160/110 Normal 28 0.6 7.8 1.35 NHBP 0.9 0.6 0.3 20 28 107 c - - M 2.4 7/10 Well Well
42. 26 39 60 + 160/110 Normal 24 0.6 6.8 1.85 NHBP 1.0 0.7 0.3 22 24 126 - - c F 2.8 7/10 Well Well
43. 27 34 61 ++ 160/110 Normal 30 0.7 9.0 1.75 NHBP 0.9 0.7 0.2 28 30 132 c - - F 1.6 8/10 Well Well
44. 23 36 49 +++ 170/120 Normal 28 0.6 8.0 1.35 NHBP 0.8 0.5 0.3 26 28 148  - - M 1.8 8/10 Well Well
45. 21 28 58 ++++ 170/120 Grade II 22 0.7 7.1 70,000 Schisto
cytes+
0.9 0.6 0.3 182 186 692 EAC - - M 800 
gm
IUD Well Dead 
Born
46. 24 38 48 + 160/110 Normal 26 0.6 8.2 1.45 NHBP 0.8 0.6 0.2 30 26 126 c - - F 2.6 8/10 Well Well
47. 26 37 62 ++ 150/120 Normal 30 0.7 8.6 2.25 NHBP 0.9 0.7 0.2 28 28 138 - -  M 2.5 7/10 Well Well
48. 30 32 64 + 150/110 Normal 30 0.8 6.7 1.25 NHBP 0.9 0.6 0.3 24 26 124  - - F 1.1 3/10 AbruptionWell
Expired
49. 24 38 60 ++ 160/110 Normal 28 0.6 6.9 1.65 NHBP 0.8 0.6 0.2 32 30 136 - -  M 2.7 8/10 Well Well
50. 28 37 61 +++ 170/120 Normal 32 0.8 7.9 1.65 NHBP 0.8 0.5 0.3 91 93 212 - - c F 2.8 8/10 Well Well
51. 18 38 47 ++ 180/110 Normal 26 0.6 8.8 1.35 NHBP 0.9 0.6 0.3 30 24 186 c - - F 2.2 8/10 Well Well
52. 29 36 49 ++ 160/110 Normal 24 0.6 9.0 1.15 NHBP 0.9 0.6 0.3 28 26 124 - -  M 1.8 8/10 Well Well
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1. 25 30 60 +++ 160/120 Grade I 22 0.6 7.1 1.15 NHBP 1.0 0.7 0.3 22 26 98  - - F 1.25 8/10 Well Well
2. 30 32 62 + 150/110 Normal 20 0.6 6.7 1.65 NHBP 0.9 0.7 0.2 20 22 96 - - c M 1.4 8/10 Well Well
3. 21 38 49 ++ 160/110 Normal 30 0.7 6.3 1.25 NHBP 0.9 0.6 0.3 28 30 126 c - - F 2.1 8/10 Well Well
4. 27 34 49 + 150/120 Normal 28 0.6 7.3 1.85 NHBP 0.9 0.6 0.3 32 30 184  - - F 1.6 8/10 Well Well
5. 23 38 60 ++ 160/110 Normal 26 0.6 7.8 1.05 NHBP 1.0 0.7 0.3 28 26 166 - - c M 2.9 7/10 Well Well
6. 19 37 62 +++ 170/110 Normal 28 0.6 8.2 1.05 Schistoc
ytes+
0.9 0.6 0.3 94 90 611 c - - F 1.8 8/10 Well Well
7. 22 36 47 ++ 160/110 Normal 24 0.6 8.0 2.25 NHBP 0.9 0.6 0.3 24 28 162  - - F 1.9 8/10 Well Well
8. 26 28 63 + 150/110 Normal 28 0.7 8.1 1.15 NHBP 0.8 0.6 0.2 26 24 126  - - M 1.0 IUD Well Dead Born
9. 31 38 54 +++ 160/120 Grade I 30 0.7 7.3 1.95 NHBP 0.8 0.5 0.3 28 24 118 - -  M 3.1 2/10 AbruptionWell Expired
10. 24 32 56 + 160/110 Normal 22 0.6 7.1 1.35 NHBP 1.0 0.6 0.4 30 28 114  - - F 1.3 8/10 Well Well
11. 28 24 66 + 150/110 Normal 24 0.6 7.0 1.85 NHBP 0.9 0.6 0.3 30 30 126 EAC - - M 550 
gm
IUD Well Dead 
Born
12. 22 36 50 +++ 170/110 Normal 20 0.6 7.0 1.25 NHBP 0.9 0.6 0.3 28 26 138  - - F 1.8 8/10 Well Well
13. 24 30 68 ++ 160/110 Normal 22 0.6 7.8 1.15 Schistoc
ytes+
0.8 0.5 0.3 86 88 608  - - F 2.0 IUD Well Dead 
Born
14. 23 37 49 ++ 170/110 Normal 18 0.6 6.7 1.35 NHBP 0.9 0.7 0.2 30 32 124 - -  F 1.9 7/10 AbruptionWell Well
15. 25 28 57 + 160/110 Normal 20 0.6 7.0 1.75 NHBP 0.9 0.6 0.3 34 32 132 EAC - - M 1.1 IUD Well Dead 
Born
16. 33 38 67 + 150/110 Normal 28 0.6 6.8 1.45 NHBP 0.8 0.6 0.2 30 28 146 - -  M 3.9 8/10 Well Well
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17. 21 30 49 Trace 150/110 Grade I 18 0.6 7.1 1.65 NHBP 0.8 0.5 0.3 26 24 138  - - F 950 
gm
8/10 Well Well
18. 29 40 61 +++ 160/120 Normal 26 0.6 6.3 1.3 NHBP 0.8 0.5 0.3 28 26 162  - - F 2.0 2/10 Well Expired
19. 20 34 47 +++ 170/110 Normal 30 0.7 6.8 1.1 NHBP 0.9 0.6 0.3 30 28 184 c - - M 1.75 8/10 Well Well
20. 32 34 56 ++ 150/110 Normal 20 0.6 6.1 1.15 NHBP 0.9 0.7 0.2 32 30 192  - - M 1.75 8/10 Well Well
21. 23 36 50 + 160/110 Normal 28 0.6 6.3 1.85 NHBP 0.9 0.6 0.3 28 32 186 - -  F 1.8 8/10 Well Well
22. 28 32 52 ++ 150/110 Normal 23 0.6 7.6 1.2 Fragme
nted 
RBC’s
0.8 0.6 0.2 124 128 652  - - M 1.4 2/10 Well Expired
23. 22 37 51 ++ 160/120 Normal 26 0.6 6.7 1.35 NHBP 0.8 0.6 0.2 28 26 126 - -  F 2.7 8/10 Well Well
24. 27 38 62 + 170/110 Normal 30 0.7 6.8 1.95 NHBP 1.0 0.7 0.3 24 22 134  - - M 2.8 8/10 Well Well
25. 34 28 55 + 160/110 Normal 28 0.6 7.0 1.45 NHBP 1.0 0.6 0.4 22 26 148 EAC - - F 900 
gm
6/10 Well Well
26. 24 40 49 +++ 180/120 Normal 32 0.7 6.7 2.05 NHBP 0.9 0.6 0.3 26 28 162 - -  M 2.9 3/10 Well Expired
27. 26 37 62 + 170/110 Normal 30 0.6 8.0 2.25 NHBP 0.8 0.6 0.2 30 26 156  - - M 1.9 7/10 Well Well
28. 31 38 59 ++ 160/120 Normal 24 0.7 7.3 1.05 Burrcells 0.9 0.5 0.4 81 84 632  
TWI
NS
- - F
F
1.8 
1.9
8/10
8/10
Well Well
29. 28 36 63 ++ 170/110 Normal 28 0.6 6.8 1.95 NHBP 0.9 0.7 0.2 32 30 106 c - - M 2.5 8/10 Well Well
30. 20 32 50 + 160/110 Normal 24 0.6 7.1 1.25 NHBP 0.8 0.5 0.3 30 28 128  - - F 1.35 8/10 Well Well
31. 30 38 62 +++ 170/120 Grade I 26 0.6 7.0 1.65 NHBP 0.9 0.6 0.3 26 28 134  - - F 2.6 7/10 Well Well
32. 22 34 49 + 160/110 Normal 20 0.6 8.0 1.05 NHBP 0.9 0.7 0.2 24 26 126 c - - F 1.9 8/10 Well Well
33. 19 38 47 + 150/110 Normal 18 0.6 8.1 1.65 NHBP 0.8 0.5 0.3 28 24 148 - -  M 2.9 7/10 Well Well
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34. 23 28 55 +++ 150/120 Grade II 20 0.7 7.3 1.35 NHBP 0.8 0.6 0.2 30 28 154 EAC - - M 1.0 IUD Well Dead 
Born
35. 26 37 67 ++ 160/110 Normal 24 0.6 7.1 1.75 NHBP 0.9 0.6 0.3 32 28 128  - - M 3.1 8/10 Well Well
36. 23 34 49 +++ 170/110 Normal 26 0.6 7.2 1.1 Schistoc
ytes+
0.9 0.6 0.3 84 86 626  - - F 2.2 IUD Well Dead 
Born
37. 21 36 59 ++ 170/110 Normal 26 0.6 6.7 1.85 NHBP 0.8 0.6 0.2 22 26 164 - -  M 1.95 8/10 Well Well
38. 28 30 68 + 160/110 Normal 28 0.7 6.8 1.65 NHBP 0.9 0.6 0.3 28 24 132 EAC - - M 900 
gm
IUD Well Dead 
Born
39. 31 34 54 +++ 170/110 Normal 24 0.6 6.8 1.25 NHBP 0.9 0.6 0.3 34 32 124 c - - F 1.7 8/10 Well Well
40. 27 28 56 + 160/110 Normal 18 0.6 6.7 2.15 NHBP 0.8 0.6 0.2 28 26 166 EAC - - M 1.0 IUD Well Dead 
Born
41. 24 37 63 + 150/110 Normal 22 0.6 6.1 1.15 NHBP 0.9 0.7 0.2 24 28 184 - -  M 3.2 7/10 Well Well
42. 28 32 60 ++ 160/110 Normal 30 0.7 7.1 1.95 NHBP 1.0 0.7 0.3 30 28 128 - -  M 1.45 IUD Well Dead 
Born
43. 27 36 54 ++ 160/120 Normal 19 0.6 6.9 1.15 Schistoc
ytes+
0.8 0.5 0.3 86 84 624  - - F 1.8 2/10 Well Expired
44. 25 38 54 +++ 170/120 Grade I 28 0.6 6.8 1.75 NHBP 1.0 0.7 0.3 20 28 176 -  - M 3.3 7/10 Well Well
45. 32 30 64 + 160/110 Normal 26 0.6 7.1 1.35 NHBP 0.9 0.6 0.3 30 26 168 EAC - - F 1.2 IUD Well Dead 
Born
46. 23 39 51 + 150/110 Normal 20 0.6 7.3 1.65 NHBP 0.8 0.5 0.3 32 30 144  - - F 2.7 7/10 Well Well
47. 29 32 62 ++ 160/120 Normal 18 0.7 6.5 1.85 NHBP 0.9 0.6 0.3 102 110 622  - - M 1.4 2/10 Well Expired
48. 33 37 54 Trace 170/110 Normal 32 0.7 8.0 1.05 NHBP 0.8 0.6 0.2 19 35 104  - - F 3.1 8/10 Well Well
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1. AP 21 P 34 51 + 140/90 Normal 22 0.6 6.2 1.15 NHBP 0.9 0.6 0.3 32 36 194 - -  F 1.95 7/10 Well Well
2. AP 18 P 28 56 ++++ 150/100 Normal 18 0.7 6.4 1.85 NHBP 0.9 0.7 0.2 75 78 604  EAC - - M 750 
gm
IUD Well Dead 
Born
3. AP 32 M 32 48 Trace 160/110 Normal 20 0.6 6.3 1.75 NHBP 0.8 0.6 0.2 26 24 112  - - M 1.9 7/10 Well Well
4. AP 26 M 30 49 ++ 160/100 Normal 22 0.6 6.7 1.45 NHBP 0.8 0.5 0.3 24 28 142 EAC - - F 1.4 7/10 Cerebral Edema 
Well
Well
5. AP 27 M 36 60 + 150/110 Normal 19 0.6 6.3 1.25 NHBP 0.9 0.6 0.3 22 26 146 - -  F 2.7 7/10 Well Well
6. AP 20 P 34 48 +++ 140/110 Grade 
I
24 0.9 8.2 75,000 Burr 
cells
0.9 0.6 0.3 254 256 686 - - c F 1.8 IUD Abruption
CRA 
Expired
Dead 
Born
7. AP 24 M 28 66 +++ 150/100 Normal 22 0.6 7.1 1.65 NHBP 0.8 0.5 0.3 24 24 162  EAC - - M 850 
gm
1/10 Well Expired
8. PP 25 M 36 58 + 140/110 Normal 20 0.7 8.0 1.75 NHBP 0.8 0.6 0.2 20 22 156 c - - M 3.5 8/10 Well Well
9. AP 19 P 38 49 + 160/120 Normal 19 0.6 8.1 1.05 NHBP 0.9 0.6 0.3 21 23 164 - -  M 3.6 7/10 Cerebral 
Edema 
GSH Well
Well
10. AP 31 M 39 60 + 160/110 Normal 18 0.7 7.2 1.85 NHBP 1.0 0.7 0.3 81 80 256 - -  F 2.7 8/10 Well Well
11. PP 25 P 38 61 ++ 170/110 Grade 
II
20 0.6 7.4 1.35 NHBP 0.9 0.6 0.3 18 16 171  - - F 2.8 8/10 Well Well
12. AP 22 M 38 49 ++ 150/110 Normal 22 0.8 7.6 1.15 Schisto
cytes+
0.9 0.6 0.3 82 86 648  - - M 2.6 8/10 Well Well
13. IP 26 P 40 58 + 150/100 Normal 24 0.6 6.4 1.7 NHBP 0.9 0.5 0.4 18 18 91 - - c F 2.6 8/10 Abruption 
Well
Well
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14. AP 30 M 28 59 ++ 160/100 Normal 26 0.7 6.3 1.25 NHBP 0.8 0.5 0.3 19 18 96 EAC - - M 1.1 2/10 HIE
GSH
Expired
15. AP 27 M 30 57 Trace 170/100 Normal 22 0.6 6.0 1.4 NHBP 0.9 0.6 0.3 22 24 101  - - F 1.3 1/10 Well Expired
16. AP 19 P 32 48 + 140/110 Grade 
I
20 0.6 7.1 1.8 NHBP 0.8 0.6 0.2 20 19 112 - -  M 1.6 IUD Well Dead 
Born
17. AP 22 P 38 49 +++ 140/100 Normal 20 0.6 6.1 2.25 NHBP 0.9 0.6 0.3 74 48 192 - -  M 2.6 8/10 Well Well
18. AP 24 M 40 58 + 140/100 Normal 18 0.6 6.0 2.15 NHBP 0.8 0.6 0.2 26 24 106 - -  F 3.0 8/10 Well Well
19. AP 23 P 34 56 +++ 150/110 Normal 22 0.7 6.4 1.15 NHBP 0.9 0.7 0.2 18 19 112 - -  F 2.7 8/10 Well Well
20. PP 23 M 32 60 + 150/100 Normal 20 0.6 6.7 1.85 NHBP 0.9 0.6 0.3 16 18 122  - - M 1.75 7/10 Well Well
21. AP 17 P 40 47 + 140/110 Normal 24 0.7 6.4 1.75 NHBP 1.0 0.7 0.3 20 22 116 - -  F 3.5 9/10 Well Well
22. AP 20 P 37 51 ++ 160/110 Grade 
II
19 0.6 7.0 1.25 NHBP 0.8 0.6 0.2 16 16 104 - -  F 2.9 9/10 Well Well
23. IP 24 M 34 62 ++++ 160/100 Normal 20 0.6 7.1 1.65 NHBP 0.8 0.5 0.3 19 17 102 -  - F 1.9 8/10 Well Well
24. AP 21 P 38 50 + 160/100 Normal 24 0.6 6.7 1.8 NHBP 0.9 0.7 0.2 72 42 110 - -  M 2.5 IUD Well Dead 
Born
25. PP 20 P 36 46 +++ 140/100 Normal 20 0.6 6.8 1.15 NHBP 0.8 0.6 0.2 18 22 126 - -  F 3.1 9/10 Well Well
26. AP 31 M 28 59 ++ 150/100 Normal 18 0.6 7.0 1.15 Burr 
cells
0.9 0.6 0.3 92 96 632 - -  M 1.6 1/10 Cerebral Edema 
Well
Expired
27. AP 27 P 30 49 + 140/110 Grade 
I
22 0.7 7.1 1.25 NHBP 0.9 0.6 0.3 20 21 140  - - F 1.4 2/10 Well Expired
28. AP 28 M 39 63 + 160/100 Normal 24 0.6 6.8 1.95 NHBP 0.8 0.6 0.2 24 22 134 c - - M 2.4 1/10 Well Expired
29. PP 26 P 40 60 ++ 170/100 Normal 17 0.6 6.7 2.25 NHBP 0.9 0.7 0.2 74 77 607  - - F 3.0 8/10 Well Well
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1 mt
30. AP 27 P 32  6
1
+ 160/110 Normal 20 0.6 7.2 1.25 NHBP 0.8 0.5 0.3 18 20 118 - -  M 1.8 IUD Well Dead 
Born
31. IP 32 M 34 63 +++ 140/100 Normal 22 0.7 7.0 1.4 NHBP 0.9 0.6 0.3 19 22 96 - -  F 2.1 8/10 Cerebral Edema 
Well
Well
32. AP 23 P 38 58 ++ 150/100 Normal 18 0.6 6.0 2.2 NHBP 0.8 0.5 0.3 24 26 102 - -  M 3.75 8/10 Well Well
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HELLP SYNDROME
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L.N. Forc
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mt
1. Mild 
PE
23 M 39 56 + 140/90 Normal 19 0.6 6.8 1.2 Schistocyt
es+
0.8 0.5 0.3 76 78 611 - -  F 3.1 8/10 Well Well
2. Severe 
PE
26 P 32 60 +++ 160/110 Grade I 20 0.6 6.2 1.05 Schistocyt
es+
0.8 0.6 0.2 116 118 672 c - - F 1.7 7/10 HIE 
Well
Well
3. Severe 
PE
23 P 34 66 ++++ 170/110 Grade I 31 0.9 8.6 80,00
0
Schistocyt
es+
2.3 1.5 0.8 261 265 684 -  - F 2.0 IUD ARF 
Expired
Dead Born
4. Severe 
PE
25 P 34 57 ++ 150/110 Normal 30 1.0 7.8 1.05 Fragmented RBC’s 0.8 0.6 0.2 362 381 674 - - LSCS Hystere
ctomy
M 1.15 8/10 Abruptiion 
ARF 
Expired 
Well
5. Severe 
PE
18 P PN 51 +++ 150/120 Grade II 23 0.7 6.8 1.15 Burr 
cells 0.9 0.6 0.3 152 148 668  
outsi
de
- - F 2.1 8/10 Well Well
6. Severe 
PE
21 P 28 58 ++++ 170/120 Grade II 22 0.7 7.1 70,00
0
Schistocyt
es+
0.9 0.6 0.3 182 186 692 EAC - - M 800 
gm
IUD Well Dead Born
7. Severe 
PE
19 M 37 62 +++ 170/110 Normal 18 0.6 8.2 1.05 Schistocyt
es+
0.9 0.6 0.3 94 90 611 C - - F 1.8 8/10 Well Well
8. Severe 
PE
24 M 30 68 ++ 160/110 Normal 22 0.6 7.8 1.15 Schistocyt
es+
0.8 0.5 0.3 86 88 608  - - F 2.0 IUD Well Dead Born
9. Severe 
PE
28 M 32 62 ++ 150/110 Normal 23 0.6 7.6 1.2 Fragmented RBC’s 0.8 0.6 0.2 124 128 652  - - M 1.4 2/10
Well Expired
10. Severe 
PE
31 M 38 59 ++ 160/120 Normal 24 0.7 7.3 1.05 Burr 
cells 0.9 0.5 0.4 81 84 632  Twin
s
- - F 
F
1.8 
1.9
8/10
8/10
              We
ll Well
11. Severe 
PE
23 M 34 49 +++ 170/110 Normal 26 0.6 7.2 1.1 Schistocyt
es+
0.9 0.6 0.3 84 86 626  - - F 2.2 IUD Well Dead Born
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12. Severe 
PE
27 M 36 54 ++ 160/120 Normal 19 0.6 6.9 1.15 Schistocyt
es+
0.8 0.5 0.3 86 84 624  - - F 1.8 2/10 Well Expired
13. AP 
Eclamp
sia
20 P 34 48 +++ 140/110 Grade I 24 0.9 8.2 75,00
0
Burr 
Cells 0.9 0.6 0.3 254 256 686 - - c F 1.8 IUD Abruption CRA 
Expired
Dead Born
14. AP 
Eclamp
sia
22 M 38 49 ++ 150/110 Normal 22 0.8 7.6 1.15 Schistocyt
es+
0.9 0.6 0.3 82 86 648  - - M 2.6 8/10 Well Well
15. AP 
Eclamp
sia
31 M 28 59 ++ 150/100 Normal 18 0.6 7.0 1.15 Burr 
Cells
0.9 0.6 0.3 92 96 632 - -  M 1.6 1/10 Cerebral 
Edema 
Well
Expired
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